0001193125-21-090543 | 20-F | XBRL Viewer

Print Document View Excel Document

Cover Page	12 Months Ended
Cover Page	Dec. 31, 2020 shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Registrant Name	Burning Rock Biotech Ltd
Entity Central Index Key	0001792267
Current Fiscal Year End Date	--12-31
Entity File Number	001-39316
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	E9
Entity Address, Country	CN
American Depositary Shares [Member]
Document Information [Line Items]
Title of 12(b) Security	American depositary shares, each representing one Class A ordinary share
Trading Symbol	BNR
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	670,191
Common Class A [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A ordinary share, par value US$0.0002 per share
Trading Symbol	BNR
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	87,223,641
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding	17,324,848

Consolidated Balance Sheet ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Current assets:
Cash and cash equivalents	¥ 1,895,308	$ 290,469	¥ 94,235
Restricted cash	29,898	4,582	4,009
Short-term investments	362,132	55,499	313,988
Accounts receivable (net of allowances of RMB13,112 and RMB24,215 (US$3,711) as of December 31, 2019 and 2020, respectively)	88,218	13,520	88,822
Contract assets	22,534	3,453	909
Amounts due from related parties	212	32	74,368
Inventories	68,021	10,425	58,116
Prepayments and other current assets	57,329	8,789	72,340
Total current assets	2,523,652	386,769	706,787
Non-current assets:
Equity method investment	1,417	217	1,790
Long-term investment	0	0	38,369
Property and equipment, net	111,481	17,085	89,314
Intangible assets, net	3,457	530	343
Other non-current assets	23,021	3,528	10,954
Total non-current assets	139,376	21,360	140,770
TOTAL ASSETS	2,663,028	408,129	847,557
Current liabilities (including amounts of the consolidated VIE and its subsidiaries without recourse to the primary beneficiary of RMB140,383 and RMB169,116(US$25,919) as of December 31, 2019 and 2020, respectively):
Accounts payable	35,482	5,438	12,348
Deferred revenue	74,402	11,403	49,539
Capital lease obligations, current	4,816	738	4,893
Accrued liabilities and other current liabilities	83,648	12,820	54,059
Customer deposits	1,120	172	4,104
Short-term borrowings	7,370	1,130	2,370
Current portion of long-term borrowings	34,695	5,317	37,129
Total current liabilities	241,533	37,018	164,442
Non-current liabilities (including amounts of the consolidated VIE and its subsidiaries without recourse to the primary beneficiary of RMB6,073 and RMB263 (US$40) as of December 31, 2019 and 2020, respectively):
Deferred government grants	263	40	991
Capital lease obligations	0	0	4,816
Long-term borrowings	0	0	18,266
Warrant liability	0	0	23,503
Other non-current liabilities	228	35	0
Total non-current liabilities	491	75	47,576
TOTAL LIABILITIES	242,024	37,093	212,018
Commitments and contingencies	0	0	0
Mezzanine equity:
Total mezzanine equity	0	0	1,527,033
Shareholders' (deficit) equity:
Ordinary shares	0	0	31
Additional paid-in capital	4,006,616	614,041	45,640
Accumulated deficits	(1,418,160)	(217,343)	(946,464)
Accumulated other comprehensive income (loss)	(167,589)	(25,683)	9,299
Total shareholders' (deficit) equity	2,421,004	371,036	(891,494)
TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' (DEFICIT) EQUITY	2,663,028	408,129	847,557
Series A Preferred Stock [Member]
Mezzanine equity:
Convertible preferred shares	0	0	186,991
Series B Preferred Stock [Member]
Mezzanine equity:
Convertible preferred shares	0	0	466,983
Series C Preferred Stock [Member]
Mezzanine equity:
Convertible preferred shares	0	0	873,059
Common Class A [Member]
Shareholders' (deficit) equity:
Ordinary shares	116	18	0
Common Class B [Member]
Shareholders' (deficit) equity:
Ordinary shares	¥ 21	$ 3	¥ 0

Consolidated Balance Sheet (Parenthetical) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥) shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 CNY (¥) shares	Dec. 31, 2019 $ / shares
Accounts Receivable, Allowance	¥ 24,215	$ 3,711	¥ 13,112
Ordinary Shares, Par value \| $ / shares		$ 0.0002		$ 0.0002
Ordinary Shares, Shares authorized	0	0	188,207,510
Ordinary Shares, Shares issued	0	0	25,031,575
Ordinary Shares, Shares outstanding	0	0	25,031,575
Series A Preferred Stock [Member]
Convertible preferred shares , Par value \| $ / shares		$ 0.0002		0.0002
Convertible preferred shares , Share authorized	0	0	33,304,544
Convertible preferred shares , Share issued	0	0	33,300,105
Convertible preferred shares , Share outstanding	0	0	33,300,105
Series B Preferred Stock [Member]
Convertible preferred shares , Par value \| $ / shares		$ 0.0002		0.0002
Convertible preferred shares , Share authorized	0	0	12,768,717
Convertible preferred shares , Share issued	0	0	12,768,717
Convertible preferred shares , Share outstanding	0	0	12,768,717
Series C Preferred Stock [Member]
Convertible preferred shares , Par value \| $ / shares		$ 0.0002		0.0002
Convertible preferred shares , Share authorized	0	0	15,719,229
Convertible preferred shares , Share issued	0	0	12,524,807
Convertible preferred shares , Share outstanding	0	0	12,524,807
Common Class A [Member]
Ordinary Shares, Par value \| $ / shares		$ 0.0002		0.0002
Ordinary Shares, Shares authorized	230,000,000	230,000,000	0
Ordinary Shares, Shares issued	87,457,081	87,457,081	0
Ordinary Shares, Shares outstanding	87,457,081	87,457,081	0
Common Class B [Member]
Ordinary Shares, Par value \| $ / shares		$ 0.0002		$ 0.0002
Ordinary Shares, Shares authorized	20,000,000	20,000,000	0
Ordinary Shares, Shares issued	17,324,848	17,324,848	0
Ordinary Shares, Shares outstanding	17,324,848	17,324,848	0
Nonrecourse [Member]
Consolidated VIE and its subsidiaries, Current	¥ 169,116	$ 25,919	¥ 140,383
Consolidated VIE and its subsidiaries, Non-current	¥ 263	$ 40	¥ 6,073

Consolidated Statements Of Comprehensive Loss ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥) ¥ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 CNY (¥) ¥ / shares shares	Dec. 31, 2018 CNY (¥) ¥ / shares shares
Revenues:
Revenues	¥ 429,903	$ 65,885	¥ 381,677	¥ 208,867
Cost of revenues:
Cost of revenues:	(115,981)	(17,775)	(108,343)	(73,808)
Gross Profit	313,922	48,110	273,334	135,059
Operating expenses:
Research and development expenses	(263,940)	(40,451)	(156,935)	(105,299)
Selling and marketing expenses (including related party amounts of RMB1,225, RMB806 and RMB543 (US$83) for the years ended December 31, 2018, 2019 and 2020, respectively)	(168,587)	(25,837)	(153,334)	(102,857)
General and administrative expenses (including related party amounts of nil, nil and RMB227 (US$35) for the years ended December 31, 2018, 2019 and 2020, respectively)	(293,800)	(45,027)	(132,157)	(88,299)
Total operating expenses	(726,327)	(111,315)	(442,426)	(296,455)
Loss from operations	(412,405)	(63,205)	(169,092)	(161,396)
Interest income	6,068	930	11,161	1,339
Interest expense	(667)	(102)	(8,989)	(17,951)
Other expense, net	(887)	(136)	(883)	(488)
Foreign exchange gain (loss) , net	(2,847)	(436)	1,486	999
Change in fair value of warrant liability	3,503	537	(2,839)	0
Loss before income tax	(407,235)	(62,412)	(169,156)	(177,497)
Income tax expenses	0	0	0	0
Net loss	(407,235)	(62,412)	(169,156)	(177,497)
Net loss attributable to Burning Rock Biotech Limited's shareholders	(407,235)	(62,412)	(169,156)	(177,497)
Accretion of convertible preferred shares	(64,688)	(9,914)	(165,011)	(54,849)
Net loss attributable to ordinary shareholders	¥ (471,923)	$ (72,326)	¥ (334,167)	¥ (232,346)
Loss per share for class A and class B ordinary shares:
Ordinary shares—basic and diluted \| (per share)	¥ 0	$ 0	¥ (14.23)	¥ (10.38)
Weighted average shares outstanding used in loss per share computation:
Ordinary shares—basic and diluted	0	0	23,483,915	22,378,876
Other comprehensive (loss) income, net of tax of nil:
Foreign currency translation adjustments	¥ (176,888)	$ (27,109)	¥ 24,104	¥ (3,929)
Total comprehensive loss	(584,123)	(89,521)	(145,052)	(181,426)
Total comprehensive loss attributable to Burning Rock Biotech Limited's shareholders	¥ (584,123)	$ (89,521)	¥ (145,052)	¥ (181,426)
Common Class A [Member]
Loss per share for class A and class B ordinary shares:
Ordinary shares—basic and diluted \| (per share)	¥ (6.88)	$ (1.05)	¥ 0	¥ 0
Weighted average shares outstanding used in loss per share computation:
Ordinary shares—basic and diluted	51,309,631	51,309,631	0	0
Common Class B [Member]
Loss per share for class A and class B ordinary shares:
Ordinary shares—basic and diluted \| (per share)	¥ (6.88)	$ (1.05)	¥ 0	¥ 0
Weighted average shares outstanding used in loss per share computation:
Ordinary shares—basic and diluted	17,324,848	17,324,848	0	0
Service [Member]
Revenues:
Revenues	¥ 311,184	$ 47,691	¥ 292,523	¥ 180,187
Cost of revenues:
Cost of revenues:	(80,132)	(12,281)	(78,837)	(60,688)
Product [Member]
Revenues:
Revenues	118,719	18,194	89,154	28,680
Cost of revenues:
Cost of revenues:	¥ (35,849)	$ (5,494)	¥ (29,506)	¥ (13,120)

Consolidated Statements Of Comprehensive Loss (Parenthetical) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Selling and Marketing Expense [Member]
Expense related to related parties	¥ 543	$ 83	¥ 806	¥ 1,225
General and Administrative Expense [Member]
Expense related to related parties	¥ 227	$ 35	¥ 0	¥ 0

Consolidated Statements Of Shareholders' (Deficit) Equity ¥ in Thousands, $ in Thousands	CNY (¥) shares	USD ($) shares	Convertible Preferred Stock [Member] CNY (¥)	Common Class A [Member] CNY (¥)	Common Stock [Member] CNY (¥) shares	Common Stock [Member] USD ($) shares	Common Stock [Member] Common Class A [Member] CNY (¥) shares	Common Stock [Member] Common Class A [Member] USD ($) shares	Additional paid-in capital [Member] CNY (¥)	Additional paid-in capital [Member] USD ($)	Additional paid-in capital [Member] Common Class A [Member] CNY (¥)	Accumulated deficit [Member] CNY (¥)	Accumulated deficit [Member] USD ($)	Accumulated deficit [Member] Convertible Preferred Stock [Member] CNY (¥)	Accumulated other comprehensive (loss) income [Member] CNY (¥)	Accumulated other comprehensive (loss) income [Member] USD ($)
Beginning balance at Dec. 31, 2017	¥ (372,156)				¥ 28				¥ 18,216			¥ (379,524)			¥ (10,876)
Beginning balance, (in shares) at Dec. 31, 2017 \| shares					22,379,924	22,379,924
Net loss	(177,497)				¥ (177,497)							(177,497)
Other comprehensive income (loss)	(3,929)														(3,929)
Repurchase of convertible preferred shares (notes 12 and 16)			¥ (127)											¥ (127)
Accretion of convertible preferred shares	54,849		(54,849)		(54,849)									(54,849)
Exercise of options (note 13)	¥ 1				¥ 1
Exercise of options (note 13),(in shares) \| shares	818,554	818,554			818,554	818,554
Repurchase of ordinary shares (note 16),(in shares) \| shares					(31,246)	(31,246)
Share-based compensation	¥ 5,095								5,095
Ending balance at Dec. 31, 2018	(603,462)				¥ 29				23,311			(611,997)			(14,805)
Ending balance, (in shares) at Dec. 31, 2018 \| shares					23,167,232	23,167,232
Net loss	(169,156)				¥ (169,156)							(169,156)
Other comprehensive income (loss)	24,104														24,104
Repurchase of convertible preferred shares (notes 12 and 16)			(300)											(300)
Accretion of convertible preferred shares	165,011		(165,011)		(165,011)									(165,011)
Exercise of options (note 13)	¥ 2				¥ 2
Exercise of options (note 13),(in shares) \| shares	1,864,343	1,864,343			1,864,343	1,864,343
Share-based compensation	¥ 22,329								22,329
Ending balance at Dec. 31, 2019	(891,494)				¥ 31				45,640			(946,464)			9,299
Ending balance, (in shares) at Dec. 31, 2019 \| shares					25,031,575	25,031,575
Net loss	(407,235)	$ (62,412)					¥ (304,440)	$ (46,658)				(407,235)
Other comprehensive income (loss)	(176,888)														(176,888)
Repurchase of convertible preferred shares (notes 12 and 16)			227											227
Accretion of convertible preferred shares	64,688	$ 9,914	¥ (64,688)				(48,359)	$ (7,411)						¥ (64,688)
Exercise of options (note 13)	¥ 1				¥ 1
Exercise of options (note 13),(in shares) \| shares	233,440	233,440			233,440	233,440
Share-based compensation	¥ 173,220								173,220
Issuance of Class A ordinary shares				¥ 1,842,193			¥ 24				¥ 1,842,169
Issuance of Class A ordinary shares,(in shares) \| shares							17,040,151	17,040,151
Conversion of all outstanding convertible preferred shares to Class A and Class B ordinary shares	1,877,705				¥ 80				1,877,625
Conversion of all outstanding convertible preferred shares to Class A and Class B ordinary shares, (in shares) \| shares					61,732,808	61,732,808
Issuance of Class A ordinary shares in connection with Employee Share Incentive Program				¥ 67,262			¥ 1				¥ 67,261
Issuance of Class A ordinary shares in connection with Employee Share Incentive Program, (in shares) \| shares							743,955	743,955
Receipt of consideration for issued ordinary shares	701								701
Ending balance at Dec. 31, 2020	¥ 2,421,004	$ 371,036			¥ 137	$ 21			¥ 4,006,616	$ 614,041		¥ (1,418,160)	$ (217,343)		¥ (167,589)	$ (25,683)
Ending balance, (in shares) at Dec. 31, 2020 \| shares					104,781,929	104,781,929

Consolidated Statements Of Cash Flows ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Cash flows from operating activities:
Net loss	¥ (407,235)	$ (62,412)	¥ (169,156)	¥ (177,497)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	33,309	5,105	31,359	24,679
Allowance for doubtful accounts	13,665	2,094	11,932	907
Allowance for Contract Assets	3,497	536	0	0
Inventory write down	911	140	432
Loss on disposal of equipment	221	34	184	37
Share of loss from an equity method investee	275	42	230	422
Share-based compensation	173,220	26,547	22,792	5,095
Accrued interest	0	0	1,811	3,738
Change in fair value of warrant liability	(3,503)	(537)	2,839	0
Changes in operating assets and liabilities:
Inventories	(9,444)	(1,447)	(8,122)	(32,251)
Accounts receivable	(13,042)	(1,999)	(65,947)	4,163
Contract assets	(25,122)	(3,850)	(196)	642
Prepayments and other current assets	7,900	1,211	(14,574)	(20,172)
Amounts due from related parties	75,222	11,528	(56,191)	(31)
Other non-current assets	0	0	(2,619)	(3,112)
Accounts payable	25,843	3,961	(3,320)	2,202
Deferred revenue	24,863	3,810	(6,307)	27,264
Accrued liabilities and other current liabilities	29,589	4,535	25,847	11,979
Customer deposits	(2,984)	(457)	1,964	1,165
Deferred government grants	(728)	(112)	(999)	1,990
Net cash used in operating activities	(73,543)	(11,271)	(228,041)	(148,780)
Cash flows from investing activities:
Proceeds from maturity of short-term investment	318,000	48,736	107,603	130,684
Proceeds from disposal of equipment	647	99	98	122
Prepayment of property and equipment	(15,286)	(2,343)	(2,361)	(1,381)
Purchase of property and equipment	(60,287)	(9,238)	(42,972)	(23,187)
Purchase of intangible assets	(3,966)	(608)	(401)	(147)
Purchase of long-term investment	0	0	(38,710)	0
Purchase of short-term investments	(348,420)	(53,398)	(369,917)	0
Net cash generated from (used in) investing activities	(109,312)	(16,752)	(346,660)	106,091
Cash flows from financing activities:
Proceeds from long-term borrowings	18,208	2,790	14,720	96,606
Proceeds from short-term borrowings	5,000	766	0	0
Proceeds from IPO and concurrent private placement ("CPP"), net of issuance costs	1,851,879	283,813	0	0
Proceeds received from capital injection	701	107	0	0
Proceeds from issuance of convertible preferred shares and warrant	269,971	41,375	657,492	2,000
Proceeds from issuance of Class A ordinary shares in connection with Employee Share Incentive Plans	67,262	10,308	0	0
Capital lease obligations payments	(4,893)	(750)	(4,664)	(2,545)
Repurchase of ordinary shares	0	0	(3,636)	0
Repayment of short-term borrowings	(5,000)	(767)	(4,630)	(3,000)
Repayment of convertible notes	(38,909)	(5,963)	(87,024)	(8,168)
Repurchase of convertible preferred shares	(3,500)	(536)	(523)	(1,500)
Net cash generated from financing activities	2,165,719	331,910	571,735	83,393
Effect of exchange rate on cash, cash equivalents and restricted cash	(155,902)	(23,893)	5,876	(159)
Net increase cash, cash equivalents and restricted cash	1,826,962	279,994	2,910	40,545
Cash, cash equivalents and restricted cash at the beginning of year	98,244	15,057	95,334	54,789
Cash, cash equivalents and restricted cash at the end of year	1,925,206	295,051	98,244	95,334
Supplemental disclosures of cash flow information:
Interest expense paid	3,549	544	10,621	13,830
Supplemental disclosures of non-cash information:
Purchase of property and equipment included in prepayments and other non-current assets	629	96	2,415	0
Purchase of property and equipment included in accounts payable	(2,709)	(415)	(599)	(190)
Purchase of property and equipment included in capital lease obligations	0	0	7,694	7,573
Extinguishment of warranty liability through exercise of warrant	19,740	3,025	0	0
Conversion of convertible notes into Series C convertible preferred shares	0	0	127,982	0
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	1,895,308	290,469	94,235	93,341
Restricted cash	29,898	4,582	4,009	1,993
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	¥ 1,925,206	$ 295,051	¥ 98,244	¥ 95,334

Organization and Basis of Presentation

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation

1.	ORGANIZATION AND BASIS OF PRESENTATION

Burning Rock Biotech Limited (the “Company”) is a limited liability company incorporated in the Cayman Islands on March 10, 2014. The Company does not conduct any substantive operations on its own but instead conducts its business operations through its subsidiaries, the variable interest entity (“VIE”) and subsidiaries of the VIE. The Company, together with its subsidiaries, the VIE and the VIE’s subsidiaries (collectively, the “Group”) are principally engaged in the developing and providing cancer therapy selection tests in the People’s Republic of China (the “PRC” or “China”).

On June 12, 2020, the Company completed its initial public offering (“IPO”) on the NASDAQ Global Select Market. The Company sold

13,500,000

ADSs, each representing

one

ordinary share, at

$16.50

per ADS (the “IPO Price”). The Underwriters exercised their options to purchase an additional

2,025,000

ADSs. Concurrently, the Company also completed a private placement offering of

1,515,151

ADSs at the IPO Price. The Company received proceeds of

US$

259,892, net of underwriting discounts and offering expenses. concurrently with the IPO. The deferred IPO costs were recorded as a reduction of the proceeds received from the IPO and private placement in shareholders’ equity.

As of December 31, 2020, the Company’s principal subsidiaries, VIE and VIE’s subsidiaries are as follows:


Entity	Date of incorporation	Place of incorporation	Percentage of legal ownership by the Company	Principalactivities
Subsidiaries
BR Hong Kong Limited	April 1, 2014	Hong Kong	100%	Investment holding

Beijing Burning Rock Biotech Co., Ltd. (the “WFOE”)	June 13, 2014	PRC	100%	Trading
Burning Rock Biotechnology (Shanghai) Co., Ltd.	July 4, 2016	PRC	100%	Research and development

VIE
Burning Rock (Beijing) Biotechnology Co., Ltd.	January 7, 2014	PRC	Nil	Holding

VIE’s subsidiaries
Guangzhou Burning Rock Dx Co., Ltd.	March 18, 2014	PRC	Nil	Cancer therapy selection test and sales of reagent kits
Guangzhou Burning Rock Medical Equipment Co., Ltd.	January 6, 2015	PRC	Nil	Facilitation of laboratory equipment sales

Guangzhou Burning Rock Biotechnology Co., Ltd.	January 23, 2018	PRC	Nil	Cancer therapy selection test and sales of reagent kits

To comply with PRC laws and regulations which prohibit and restrict foreign ownership of business involving the development and application of genomic diagnosis and treatment technology, the Group conducts its business in the PRC principally through the VIE and the VIE’s subsidiaries. The equity interests of the VIE are legally held by PRC shareholders (the “Nominee Shareholders”).

Despite the lack of majority ownership, the Company through the wholly foreign owned entity (“the WFOE”) has effective control of the VIE through a series of contractual arrangements (the “VIE agreements”) and a parent-subsidiary relationship exists between the WFOE and the VIE since 2014. Through the VIE agreements, the Nominee Shareholders of the VIE effectively assigned all of their voting rights underlying their equity interests in the VIE to the WFOE, and therefore, the WFOE has the power to direct the activities of the VIE that most significantly impact its economic performance. The WFOE also has the right to receive economic benefits that potentially could be significant to the VIE. Therefore, the WFOE is considered the primary beneficiary of the VIE and consolidates the VIE in accordance with Accounting Standards Codification (“ASC”) Topic

810-10

(“ASC 810-10”)

, Consolidation: Overall.

The following is a summary of the VIE agreements:

Exclusive Business Cooperation Agreement

Pursuant to the exclusive business cooperation agreement entered into amongst the WFOE and the VIE on June 20, 2014, the WFOE provides exclusive business support, technology services and consulting services in return for service fees, which is adjustable at the sole discretion of the WFOE. Without the WFOE’s consent, the VIE cannot procure services from any third party or enter into similar service arrangements with any other third party, except for the ones appointed by the WFOE. The agreement was effective for 20 years from June 20, 2014 and automatically renew for 10 years if all parties have no objection.

Power of Attorney

The Nominee Shareholders signed Power of Attorney on June 20, 2014 to irrevocably appoint the WFOE, or its designated party, as the

attorney-in-fact

to exercise rights on the Nominee Shareholders’ behalf any and all rights that such shareholder has in respect of its equity interest in the VIE such as the right to appoint or remove directors, supervisors and officers, as well as the right to sell, transfer, pledge or dispose of all or any portion of the equity interests held by such shareholder, or of the assets held by the VIE. This agreement will remain effective until it is terminated by the WFOE.

Exclusive Option Agreement

Pursuant to the exclusive option agreements entered into amongst the VIE, the Nominee Shareholders and the WFOE on June 20, 2014, the Nominee Shareholders irrevocably granted the WFOE an exclusive option to request the Nominee Shareholders to transfer or sell any part or all of its equity interests in the VIE to the WFOE, or its designees. The purchase price of the equity interests in the VIE is equal to the minimum price required by PRC law. Any proceeds received by the Nominee Shareholders from the exercise of the right shall be remitted to the WFOE, to the extent permitted under the PRC laws. Without the WFOE’s prior written consent, the VIE and the Nominee Shareholders may not amend its articles of association, increase or decrease the registered capital, sell or otherwise dispose of its assets or beneficial interest, create or allow any encumbrance on its assets or other beneficial interests, provide any loans or guarantees and request any dividends or other form of assets. This agreement is not terminated until all of the equity interest of the VIE has been transferred to the WFOE or the person(s) designated by the WFOE.

Pursuant to the equity interest pledge agreements entered into amongst the WFOE, the VIE and the Nominee Shareholders on June 20, 2014, the Nominee Shareholders pledged all of their equity interests in the VIE to the WFOE as collateral to secure their obligations under the exclusive business cooperation agreement. The WFOE is entitled to all dividends during the effective period of the share pledge except as it agrees otherwise in writing. If the VIE or any of the Nominee Shareholders breaches its contractual obligations, the WFOE is entitled to certain rights regarding the pledged equity interests, including the right to receive proceeds from the auction or sale of all or part of the pledged equity interests of VIE in accordance with PRC law. The Nominee Shareholders agree not to create any encumbrance on or otherwise transfer or dispose of their respective equity interests in the VIE, without the prior consent of the WFOE.

The Power of Attorney, Exclusive Option Agreement and Equity Interest Pledge Agreement were amended and restated on August 27, 2015, July 1, 2016, April 19, 2018 and January 4, 2019 to reflect the new nominee shareholders appointed by the Series A, Series B and Series C preferred shareholders and the resulting equity ratio adjustments from the preferred shareholders’ investment.

On October 21, 2019, the VIE Agreements were supplemented by the following terms:

(1) Exclusive option agreement

•

The VIE irrevocably grants the WFOE an exclusive asset purchase option whereby the WFOE has the right to purchase or designate another party to purchase part or all of the assets of the VIE as permitted under the PRC laws. The purchase price of the VIE’s assets is equal to the book value of the assets or the minimum price as permitted by applicable PRC law, whichever is higher; and

•

The WFOE has the right to unilaterally amendment, supplement and termination of this agreement.

(2) Exclusive Business Cooperation Agreement

•

In exchange for these services, the VIE will pay a service fee, equal to the VIE’s profit before tax, after recovering any accumulated losses of the VIE and its subsidiaries from the preceding fiscal year, and deducting working capital, expenses, tax and a reasonable amount of operating profit according to applicable tax law principles and tax practice; and

•

The agreement will be in effect for 10 years unless the WFOE unilaterally terminates the agreement by giving written notification at least thirty days prior to the expiration of the agreement. The WFOE may at its sole discretion unilaterally extend the term of this agreement prior to its expiration upon notice to the VIE.

(3) Equity Interest Pledge Agreement

•

The Nominee Shareholders pledged all of their respective equity interests in the VIE to the WFOE as continuing first priority security interest to guarantee the performance of these Nominee Shareholders and the VIE’s obligations under the power of attorney, the exclusive option agreement and the exclusive business cooperation agreement; and

•

This agreement will remain effective until all the contractual obligations have been satisfied in full under all the agreements mentioned above.

(4) Financial support undertaking letter

•

Pursuant to the financial support undertaking letter, the Company is obligated and hereby undertakes to provide unlimited financial support to the VIE, to the extent permissible under the applicable PRC laws and regulations, whether or not any such operational loss is actually incurred. The Company will not request repayment of the loans or borrowings if the VIE or its Nominee Shareholders do not have sufficient funds or are unable to repay.

(5) Voting proxy agreement

•

Pursuant to the voting proxy agreement, the WFOE irrevocably and unconditionally commits to execute its rights under the power of attorney in accordance with the instructions from the Company.

As a result of the amended agreements on October 21, 2019, the power and the rights pursuant to the power of attorney have since been effectively reassigned to the Company which has the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance. The Company is also obligated to absorb the expected losses of the VIE through the financial support as described above. The Company and the WFOE, as a group of related parties, hold all of the variable interests of the VIE. The Company has been determined to be most closely associated with the VIE within the group of related parties and has replaced the WFOE as the primary beneficiary of the VIE since October 2019. As the VIE was subject to indirect control by the Company through the WFOE immediately before and direct control immediately after the VIE Agreements were supplemented, the change of the primary beneficiary of the VIE was accounted for as a common control transaction based on the carrying amount of the net assets transferred.

In the opinion of the Company’s legal counsel, (i) the ownership structure of the WFOE and its VIE is in compliance with PRC laws and regulations; (ii) the contractual arrangements with the VIE and their shareholders are valid and binding, and not in violation of current PRC laws or regulations; (iii) the voting proxy agreement between the Company and the WFOE is valid in accordance with the articles of association of the Company and Cayman Islands Law.

However, uncertainties in the PRC legal system could cause the relevant regulatory authorities to find the current VIE Agreements and businesses to be in violation of any existing or future PRC laws or regulations and could limit the Company’s ability to enforce its rights under these contractual arrangements. Furthermore, the nominee shareholders of the VIE may have interests that are different from those of the Company, which could potentially increase the risk that they would seek to act contrary to the terms of the contractual agreements with the VIE.

In addition, if the current structure or any of the contractual arrangements were found to be in violation of any existing or future PRC laws or regulations, the Company may be subject to penalties, including but not be limited to, revocation of business and operating licenses, discontinuing or restricting business operations, restricting the Company’s right to collect revenues, temporary or permanent blocking of the Company’s internet platforms, restructuring of the Company’s operations, imposition of additional conditions or requirements with which the Company may not be able to comply, or other regulatory or enforcement actions against the Company that could be harmful to its business. The imposition of any of these or other penalties could have a material adverse effect on the Company’s ability to conduct its business.

The following table sets forth the assets and liabilities of the VIE and subsidiaries of the VIE included in the Group’s consolidated balance sheets:


	As of December 31,
	2019		2020
	RMB		RMB		US$

Cash and cash equivalents		28,102		149,736		22,948
Restricted cash		4,009		263		40
Accounts receivable (net of allowances of RMB12,665 and RMB23,983 (US$3,676) as of December 31, 2019 and 2020, respectively)		88,555		88,217		13,520
Contract assets		909		22,534		3,453
Amounts due from related parities		2,052		212		32
Inter-company receivables*		7,232		8,432		1,292
Inventories		49,662		61,374		9,406
Prepayments and other current assets		15,931		17,548		2,692

Total current assets		196,452		348,316		53,383

Property and equipment, net		33,246		32,342		4,957
Intangible assets, net		91		77		12
Other non-current assets		3,171		5,797		888

Total non-current assets		36,508		38,216		5,857

TOTAL ASSETS		232,960		386,532		59,240


Accounts payable		10,068		26,871		4,118
Deferred revenue		49,539		74,402		11,403
Inter-company payables*		273,772		495,526		75,943
Capital lease obligations, current		4,893		4,816		738
Accrued liabilities and other current liabilities		38,422		54,271		8,317
Customer deposits		4,104		1,120		172
Short-term borrowings		2,370		7,370		1,130
Current portion of long-term borrowings		30,987		266		41

Total current liabilities		414,155		664,642		101,862

Deferred government grant		991		263		40
Capital lease obligations		4,816		—		—
Long-term borrowings		266		—		—

Total non-current liabilities		6,073		263		40

TOTAL LIABILITIES		420,228		664,905		101,902

*	Inter-company receivables/payables represent balances of VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries.

The table sets forth the results of operations of the VIE and subsidiaries of the VIE included in the Group’s consolidated statements of comprehensive loss:


	For the years ended December 31,
	2018			2019			2020
	RMB			RMB			RMB			US$

Revenues		204,310			381,460			432,142			66,229
Net loss		(93,455	)		(72,015	)		(244,765	)		(37,510	)

The table sets forth the cash flows of the VIE and subsidiaries of the VIE included in the Group’s consolidated statements of cash flows:


	For the years ended December 31,
	2018			2019			2020
	RMB			RMB			RMB			US$

Net cash (used in) generated from operating activitie s		(44,153	)		(4,993	)		158,563			24,301
Net cash used in investing activities		(7,908	)		(56,052	)		(9,795	)		(1,501	)
Net cash generated from (used in) financing activities		79,261			34,540			(30,880	)		(4,733	)

As of December 31, 2019 and 2020, there were no pledges or collateralization of the assets of the VIE and the VIE’s subsidiaries. The amount of the net liabilities of the VIE and subsidiaries of VIE was RMB187,268 and RMB278,373 (US$42,662

)

as of December 31, 2019, and 2020, respectively. The creditors of the VIE and subsidiaries of the VIE’s third-party liabilities did not have recourse to the general credit of the primary beneficiary in the normal course of business. The VIE holds certain assets, including detection equipment and related equipment for use in their operations. The Company did not provide nor intend to provide additional financial or other support not previously contractually required to the VIE and subsidiaries of the VIE during the years presented.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompany consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”).

Certain prior year amounts in the consolidated statements of comprehensive loss have been reclassified to conform to the current year presentation.

Principles of consolidation

The consolidated financial statements of the Group include the financial statements of the Company, its subsidiaries, the VIE and the VIE’s subsidiaries for which the Company is the primary beneficiary of the VIE. All significant intercompany balances and transactions have been eliminated upon consolidation.

Use of estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in the Group’s consolidated financial statements include, but are not limited to, allowance for doubtful accounts for accounts receivable and contract assets, inventory provision, standalone selling prices of performance obligations, the useful lives and impairment of long-lived assets, the fair value of share-based awards, the fair value of warrant liability and breakage income. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.

Foreign currency translation

The functional currency of the Company and BR Hong Kong Limited is US$. The functional currency of the Company’s PRC subsidiaries, the VIE and the VIE’s subsidiaries is RMB. The determination of the respective functional currency is based on the criteria stated in ASC 830,

Foreign Currency Matters

. The Company uses RMB as its reporting currency. The financial statements of the Company and the Company’s subsidiary outside PRC are translated from the functional currency to the reporting currency.

Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People’s Bank of China (the “PBOC”) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are

re-measured

at the exchange rates prevailing at the balance sheet date.

Non-monetary

items that are measured in terms of historical costs in foreign currency are

re-measured

using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.

Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as accumulated comprehensive (loss) income and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.

Convenience translation

Translations of amounts from RMB into US$ for the convenience of the reader have been calculated at the exchange rate of RMB6.5250 per US$1.00 on December 31, 2020, as published on the website of the United States Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at such rate or at any other rate.

Cash and cash equivalents

Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.

Restricted cash

Restricted cash primarily represent deposits restricted in designated bank accounts for specific uses in relation to certain government grants received.

In November 2016, the FASB issued Accounting Standard Update (“ASU”)

No. 2016-18,

Statement of Cash Flows (Topic 230): Restricted Cash

, which requires entities to present the aggregate changes in cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, the statement of cash flows will be required to present restricted cash and restricted cash equivalents as a part of the beginning and ending balances of cash and cash equivalents. The Group early adopted the updated guidance retrospectively and presented restricted cash within the ending cash, cash equivalents and restricted cash balance on the Group’s consolidated statements of cash flows for the years ended December 31, 2018, 2019 and 2020.

Accounts receivable and allowance for doubtful accounts

Accounts receivable are carried at net realizable value. The Group records allowance for doubtful accounts in the period when collection is no longer probable. The Group considers specific evidence when evaluating the collectability of accounts receivables, including the aging of the receivable, customer payment history, customer’s credit worthiness and other factors. Accounts receivable are written off when management determines a balance is uncollectable after all collection efforts have ceased.

Short-term

investment

All highly liquid investments with maturities of greater than three months, but less than twelve months, are classified as short-term investments. Short-term investments held by the Group represented time deposits of remaining maturities of greater than three months but less than twelve months.

Fair value measurements

The Group applies ASC 820,

Fair Value Measurements and Disclosures

. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets

Level 2 - Include other inputs that are directly or indirectly observable in the marketplace

Level 3 - Unobservable inputs which are supported by little or no market activity

ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.

The carrying amounts of cash and cash equivalent, restricted cash, short-term investments, accounts receivable, amounts due from and due to related parties, accounts payable and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amounts of long-term borrowings and long-term investment approximate their fair values since they bear interest at rates which approximate market interest rates.

On January 22, 2020, the holder of the Series C convertible redeemable preferred shares warrants (the “Series C Warrant”) exercised its Series C

Warrant and purchased

1,064,950 Series C convertible redeemable preferred shares (

ote 12). The Group recognized a gain from the

decrease in warrant fair value

of RMB3,503 (US$537) for the year ended December 31, 2020. The Group recognized a loss from the increase in fair value of RMB2,839 for the year ended December 31, 2019.

The Group records fair value change of the warrant as a component of non-operating income (expense) in the consolidated statement of comprehensive loss.

The Group measured the fair value of its warrant liability on a recurring basis using significant unobservable (Level 3) inputs as of December 31, 2019. The valuation technique, inputs and corresponding impact to the fair value are as follows:


Financial instrument	Valuation technique	Unobservable input	Estimation
Warrant liability	Black-Scholes option pricing model	Volatility for Black-Scholes option pricing model		45	%
		Market value of the underlying Series C Preferred Shares	US$	12.08

The following table presents a reconciliation of all financial instruments measured at fair value on a recurring basis using Level 3 unobservable inputs:


	Warrant liability
	RMB
Balance as of December 31, 2019		23,503
Fair value change		(3,503	)
Foreign exchange translation		(260	)
Exercise of Series C Warrant ( N ote 12)		(19,740	)

Balance as of December 31, 2020		—

The amount of total gain for the year ended December 31, 2020 included in losses (RMB)		3,503
The amount of total gain for the year ended December 31, 2020 included in losses (US$ )		537

The Group did not transfer any assets or liabilities in or out of Level 3 during the years ended December 31, 2019 and 2020. As of December 31, 2020, there were no warrants outstanding. Therefore, there was no asset or liability measured at fair value using Level 3 unobservable inputs on a recurring basis as of December 31, 2020.

The Group had no financial assets and liabilities measured and recorded at fair value

on a non-recurring basis as of December 31, 2019 and 2020.

Inventories

Inventories consist of raw materials, work in progress and finished goods which are stated at the lower of cost and net realizable value. Cost is determined using the weighted average method. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for decreases in sales price, obsolescence, or similar reductions in the estimated net realizable value, and recorded in cost of sales.

Equity method investment

Equity method investments represent investments in entities in which the Group can exercise significant influence but does not own a majority equity interest or control

and

are accounted for using the equity method of accounting in accordance with ASC Subtopic

323-10,

Investments-Equity Method and Joint Ventures: Overall

. Under the equity method, the Group initially records its investment at cost and prospectively recognizes its proportionate share of each equity investee’s net profit or loss into its consolidated statements of operations. The difference between the cost of the equity investee and the amount of the underlying equity in the net assets of the equity investee is recognized as equity method goodwill included in equity method investments on the consolidated balance sheets. The Group evaluates its equity method investments for impairment under ASC

323-10.

An impairment loss on the equity method investments is recognized in the consolidated statements of comprehensive loss when the decline in value is determined to be other-than-temporary.

In January 2017, the Group acquired for 20.29% equity interest in EaSuMed Holding Ltd.

an amount of US$363. In October 2020, additional shares were allotted to the Group from EaSuMed Holding Ltd. and therefore the Group held

21.04% equity interest in EaSuMed Holding Ltd. as of December 31, 2020. The Group exercised significant influence over the investee with its one seat on the board of directors and accounted for its investment under the equity method. The Group recognized loss

from equity method investment of RMB422, RMB230 and RMB275 (US$42) for the years ended December 31, 2018, 2019 and 2020, respectively. No impairment loss was recognized for the years presented.

Property and equipment, net

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:


Category		Estimated Useful Life
Machinery and laboratory equipment		5 years
Vehicles		6 years
Furniture and tools		5 years
Electronic equipment		3 years
Leasehold improvements		Lesser of lease terms or estimated useful lives of the assets

Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property and equipment are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation from the asset and accumulated depreciation accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.

Direct costs that are related to the construction of property and equipment, and incurred in connection with bringing the assets to their intended use are capitalized as construction in progress. Construction in progress is transferred to specific property and equipment, and the depreciation of these assets commences when the assets are ready for their intended use.

Intangible assets, net

Intangible assets are carried at cost less accumulated amortization and any recorded impairment. Intangible assets with finite useful lives are amortized using a straight-line method of amortization that reflects the estimated pattern in which the economic benefits of the intangible asset are to be consumed. The estimated useful life for the intangible assets is as follows:


Category		Estimated Useful Life
Computer software		3 years

The Group does not have any indefinite-lived intangible assets.

Impairment of long-lived assets

The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets’ remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.

No impairment loss was recorded for the years ended December 31, 2018, 2019 and 2020.

Segment reporting

In accordance with ASC 280,

Segment Reporting

. The Group’s chief operating decision maker (“CODM”) has been identified as the Chief Executive Officer. The Group’s CODM evaluates segment performance based on revenues and gross profit by the operating segments of central laboratory business,

in-hospital

business and pharma research and development services. Substantially all of the Group’s revenues are derived from within the PRC.

Revenue recognition

The Group derives revenues from its central laboratory business, in-hospital business and pharma research and development services. The Group recognizes revenue to depict the transfer of promised products or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those products or services.

Revenue from central laboratory business

Revenue from central laboratory business is primarily generated through the sales of the Group’s cancer therapy selection test, to individual patient customers. The individual patient prepays the consideration in full and the transaction price for each contract is fixed at contract inception. The patient can choose to purchase a single cancer therapy selection test or a package which consists of multiple cancer therapy selection tests of the same type or a combination of different types of cancer therapy selection tests. Each cancer therapy selection test represents a single performance obligation. Revenue is allocated to each performance obligation based on the relative standalone selling price method. The Group records revenue at a point in time, when each cancer therapy selection testing report is delivered to the patient.

The group launched cancer therapy selection testing packages (“Monitoring Packages”) in 2017. Each monitoring package contain a fixed number of the same type cancer therapy selection test which can be used up to two years from purchase date. Based on historical usage rates, a portion of the cancer therapy selection tests within the Monitoring Packages are not expected to be used by the patient prior to expiration, referred to as a “breakage”. The Group recognizes the expected breakage amount as revenue in proportion to the total number of tests expected to be performed for patients prior to the expiration date. If the Group is not expected to be entitled to a breakage amount due to the lack of historical experience, the expected breakage amount is recognized as revenue at the end of the two year period when the monitoring package expires. The Group evaluates its breakage estimates periodically based upon its historical experience with each type of Monitoring Packages recent usage pattern prior to the expiration period. The historical usage rates may not be reflective of the actual usage rates due to changes in patient behavior and medical advancements. The determination of whether the Group has accumulated sufficient historical experience to determine breakage amount, and changes in the actual patients’ usage rates may significantly impact on the amount of breakage revenue recognized for the period. The Group changed its estimates of the entitlement of breakage amount in 2019 as the Group concluded it has sufficient historical experience to estimate breakage. The Group recognized breakage income breakage income

of nil, RMB14,723 and RMB11,900 (US$1,824)

for the years ended December 31, 2018, 2019 and 2020, respectively.

Revenue from

in-hospital

business

Revenue from

in-hospital

business is primarily generated through reagent kit sales and providing facilitation services for laboratory equipment sold to hospitals. The Group manufactures the reagent kits and sells to the hospitals when the hospitals submit a purchase order. Each reagent kit represents a single performance obligation. The Group does not provide rights of return for the reagent kits sold other than returns of defective products. Returns for defective products were not material for the periods presented. Revenue is allocated to each performance obligation based on a relative standalone selling price basis using the expected cost plus a margin method. The Group records revenue on the sales of reagent kits at a point in time when the reagent kits are delivered to the hospital.

For the facilitation services, the Group purchases the laboratory equipment from third-party suppliers when the hospital submits purchase request and resells the laboratory equipment to the hospital. The Group acts as an agent in facilitating laboratory equipment sales as it does not control the laboratory equipment prior to its delivery to the hospitals and does not have inventory risks. The facilitation services for each piece of laboratory equipment represents a single performance obligation. The Group records revenue on a net basis at the point in time when the Group has completed its facilitation services.

Revenue from pharma research and development services

The Group provides pharma research and development services to pharmaceutical companies for developing new targeted therapies and immunotherapies on various types of cancers and to hospitals for their studies on cancer diagnosis and treatment. The pharma research and development services include a range of cancer therapy selection testing services, analytical validation services and project management services. The Group will deliver an analysis report upon the completion of services. The testing services, analytical validation services and project management services are not distinct within the context of the contract because the Group is using these services as inputs to produce the analysis report. The Group recognizes services revenue over the period in which these services are provided because the Group does not create an asset with alternative use to the Group and the Group has an enforceable right to payment for the performance completed to date. The Group recognizes revenue using an output method to measure progress that utilizes cancer therapy selection testing performed to date as its measure of progress.

Pharmaceutical companies may also separately engage the Group to perform multiple cancer therapy selection tests without an analysis of the test results. Each therapy selection test is capable of being distinct and separately identifiable from other promises in the contracts and therefore, represent distinct performance obligations. Revenue is allocated to each cancer therapy selection test using a relative standalone selling price basis. The Group records revenue at a point in time, when each cancer therapy selection test result is delivered to the pharmaceutical companies and hospitals.

Contract assets and liabilities

When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration or before payment is due, the Group recognizes its conditional rights to consideration as a contract asset, which is presented as “contract assets” on the consolidated balance sheets. The contract assets are transferred to the receivables when the rights become unconditional. When a customer pays consideration before the Group provides products or services, the Group records its obligation as a contract liability, which is presented as “deferred revenue” on the consolidated balance sheets.

Contract assets increased RMB21,625 (US$3,314) compared to the year ended December 31, 2019 because the Group has an unconditional right to bill customers only upon delivery of all reagent kits and the Group did not deliver all of the reagent kits in certain revenue arrangements with hospitals as of December 31, 2020. The Group recorded an impairment loss on contract assets of nil, nil and RMB3,497 (US$536) for the years ended December 31, 2018, 2019 and 2020, respectively. The increase

in deferred revenue of RMB24,863 (US$3,810) as compared to the year ended December 31, 2019 is a result of the increase in consideration received from the Group’s customers. The Group receives payments from customers based on a billing schedule as established in contracts. Revenue recognized that was included in deferred revenue balance at the beginning of the year was RMB26,587, RMB41,255 and RMB27,807 (US$4,262

)

for the years ended December 31, 2018, 2019 and 2020, respectively.

The transaction prices allocated to the remaining performance obligations (unsatisfied or partially satisfied) as of December 31, 2019 and 2020 were RMB56,110 and RMB115,523 (US$17,705), respectively. The Group expects to recognize the related revenue within one year.

Value added taxes and related surcharges

The Group is subject to value added tax (the “VAT”) that is imposed on and concurrent with the revenues earned for services provided in the PRC. The Group’s applicable value added tax rate is 6% or 17%. Pursuant to further VAT reform implemented from May 1, 2018,

the previous applicable VAT tax rates of

17% were adjusted to 16% and further adjusted to 13% beginning

April 2019.

The Group excludes VAT from the measurement of transaction price because the Group is collecting the VAT on behalf of tax authorities. The Group is also subject to surcharges on VAT payments in accordance with PRC law, which is recorded as cost of revenue. Surcharges are recorded when incurred because they are not imposed on and concurrent with a specific revenue arrangement and were immaterial for the years ended December 31, 2018, 2019 and 2020, respectively.

Research and development expenses

Research and development expenses primarily consist of salaries and benefits for research and development personnel and the cost of materials for research and development projects and products. The Group expenses research and development costs as they are incurred.

Government subsidies

Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the local governments. The government subsidies with certain operating conditions are recorded as liabilities when received and will be recorded as a reduction of the related expense when the conditions are met. The government subsidies with no further conditions to be met are recorded as other income when received. Where the grant relates to an asset, it is recognized as deferred government grant and released to the consolidated statements of comprehensive loss in equal amounts over the expected useful life of the related asset as a reduction of the related expense.

Leases

The Group classifies leases as either operating or capital leases at inception date. The Group assesses a lease to be a capital lease if any of the following conditions exists: a) ownership

is transferred to the lessee by the end of the lease term, b) there is a bargain purchase option, c) the lease term is at least 75% of the property’s estimated remaining economic life or d) the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease.

All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over their respective lease terms. The Group leases certain office space and network equipment under

non-cancelable

operating lease agreements. Certain lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purpose of recognizing lease expense on straight-line basis over the term of the lease.

Comprehensive loss

Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive (loss) income of the Group includes foreign currency translation adjustments related to the Group and its overseas subsidiaries, whose functional currency is US$.

Income taxes

The Group follows the liability method of accounting for income taxes in accordance with ASC 740,

Income Taxes

(“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.

The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements. The Group recognizes in the consolidated financial statements the benefit of a tax position which is “more likely than not” to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Group’s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expenses.

Share-based compensation

The Group applies ASC 718,

Compensation — Stock Compensation

(“ASC 718”), to account for its employee share-based payments awards granted to certain directors, executives and employees. Share options granted are classified as equity awards and are measured based on the grant date fair value of the equity instrument issued. For employee award with only service condition, the Group record compensation costs using the straight-line method over the requisite service period, which is generally the vesting period of the options, with a corresponding impact reflected in additional

paid-in

capital. For employee award with service condition and performance condition that has graded vesting schedule, the Group record compensation costs on a

tranche-by-tranche

basis, with a corresponding impact reflected in additional

paid-in

capital. The Group early adopted ASU

No. 2016-09

Compensation-Stock Compensation (Topic 718): Improvement to Employee Share-based Payment Accounting (“ASU

2016-09”)

and accounts for forfeitures as they occur.

Loss per share

In accordance with ASC 260,

Earnings Per Share

, basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the

two-class

method. Under the

two-class

method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. The Company’s convertible preferred shares are participating securities because they are entitled to receive dividends or distributions on an as converted basis. Diluted loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the conversion of the convertible preferred shares using the

if-converted

method, and ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic loss per share using the

two-class

method is not applicable as the Company is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Company.

Employee defined contribution plan

As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees’ salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group’s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of RMB20,566, RMB29,825 and RMB28,232 (US$4,327) for the years ended December 31, 2018, 2019 and 2020, respectively.

Modification of redeemable convertible preferred shares

The Group assesses whether an amendment to the terms of its redeemable convertible preferred shares is an extinguishment or a modification using the fair value model. If the fair value of the redeemable convertible preferred shares immediately after the amendment changes by more than ten percent from the fair value of the redeemable convertible preferred shares immediately before the amendment, the amendment is considered an extinguishment. An amendment that does not meet this criterion is a modification. When redeemable convertible preferred shares are extinguished, the difference between the fair value of the consideration transferred to the redeemable convertible preferred shareholders and the carrying amount of the redeemable convertible preferred shares (net of issuance costs) is treated as a deemed dividend to the redeemable convertible preferred shareholders. When redeemable convertible preferred shares are modified, the increase of the fair value immediately after the amendment is treated as a deemed dividend to the redeemable convertible preferred shareholders. Modifications that result in a decrease in the fair value of the redeemable convertible preferred shares are not recognized.

Concentration of risks

Concentration of credit risk

As of December 31 2020, the Group had R

MB2,287,338 (US$350,550) in cash and cash equivalents, restricted cash, and short-term investments, 55% and 45% of which were held by financial institutions in the PRC and international financial institutions outside of the PRC, respectively. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.

Accounts receivables are typically unsecured and denominated in RMB and are derived from revenues earned from reputable customers. No customer accounted for more than 10% of the Group’s total accounts receivable balance as of December 31, 2018. As of December 31, 2019 and 2020, the Group had two customers with a receivable balance exceeding 10% of the total accounts receivable balance. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.

Concentration of suppliers

A significant portion of the Group’s equipment and raw materials were purchased from its two suppliers, who collectively accounted for 52%, 67% and 57% of the Group’s total equipment and raw materials purchases for the years ended December 31, 2018, 2019 and 2020, respectively.

Business and economic risk

The Group believes that changes in any of the following areas could have a material adverse effect on the Group’s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group’s ability to attract employees necessary to support its growth. The Group’s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.

Currency convertibility risk

Substantially all of the Group’s businesses are transacted in RMB, which is not freely convertible into foreign currencies. On January 1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the People’s Bank of China (the “PBOC”). However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts.

Foreign currency exchange rate risk

From July 21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For US$ against RMB, there was appreciation

of approximately 5.7% and 1.3%, depreciation of approximately 6.3% in the years ended December 31, 2018, 2019 and 2020 respectively.

The functional currency and the reporting currency of the Company are the US$ and the RMB, respectively. Most of the revenues and costs of the Group are denominated in RMB, while a portion of cash and cash equivalents are denominated in US$. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the US$ in the future. Any significant fluctuation of the valuation of RMB may materially affect the Group’s cash flows, revenues, earnings and financial position, and the value of any dividends payable on the ADS in US$.

Reverse share split

On January 30, 2020, the Company’s board of directors and shareholders approved an amended and restated memorandum and articles of association of the Company to effect a reverse split of shares of all issued and unissued shares of the Company (including stock options issued or issuable to employees and directors) as well as issued and outstanding Preferred Shares, on a

2-for-1

basis (the “Reverse Share Split”). The par values and the authorized shares of the ordinary shares, preferred shares were adjusted as a result of the Reverse Share Split. The Reverse Share Split became effective on January 30, 2020. All ordinary shares, preferred shares, and

the

related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Share Split for all periods presented.

Recently issued accounting pronouncements

The Group is an emerging growth company (“EGC”) as defined by the Jumpstart Our Business Start-ups Act (“JOBS Act”). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.

In February 2016, the FASB issued ASU

No. 2016-02

(“ASU

2016-02”),

Leases

(Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU

No. 2018-10

(“ASU

2018-10”),

Codification Improvements to Topic 842, Leases

, which clarifies certain aspects of the guidance issued in ASU

2016-02;

and ASU

No. 2018-11

(“ASU

2018-11”),

Leases (Topic 842): Targeted Improvements

, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity’s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). In November 2019, the FASB issued ASU

No. 2019-10,

Financial

Instruments - Credit Losses

(Topic 326),

Derivatives and Hedging (Topic 815), and Leases (Topic 842), Effective Dates

(“ASU

2019-10”),

which extends the adoption date for certain registrants. The updated guidance is effective for the Group for annual reporting periods beginning January 1, 2021 and interim periods within annual periods beginning January 1, 2022.

Early adoption is permitted. The Group plans to early adopt the new lease standard and the Group

expects that applying the ASU

2016-02

would materially increase the assets and liabilities due to the recognition of

right-of-use

assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows.

In June 2016, the FASB issued ASU

No. 2016-13,

Financial Instruments - Credit Losses

(Topic 326): Measurement of Credit Losses on Financial Instruments

(“ASU

2016-13”).

ASU

2016-13

is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group’s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, the FASB issued ASU

2019-10,

which extends the adoption date for certain registrants. The amendments in ASU

2016-13

are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023.

The Group plans to early adopt the credit losses standard and expects that applying ASU 2016-13 would increase the allowance accounts receivable and contract assets.

In December 2019, the FASB issued ASU 2019-12,

Simplifying the Accounting for Income Taxes

to remove specific exceptions to the general principles in Topic 740 and to simplify accounting for income taxes. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The Group is currently evaluating the impact of this accounting standard update on its consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01,

Clarifying the interactions between Topic 321, Topic 323 and Topic 815.

The amendments in this Update clarify certain interactions between the guidance for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. The amendment in ASU 2020-01 are effective for public business entities in fiscal years beginning after December 15, 2020 and fiscal years beginning after December 15, 2021 for all other entities. Early adoption is permitted. The Group is in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.

Segment Reporting

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Segment Reporting

3	SEGMENT REPORTING

For the years ended December 31, 2018, 2019 and 2020, the Group had three operating segments, including central laboratory business,

in-hospital

business and pharma research and development services. The operating segments also represented the reporting segments. The Group’s CODM assess the performance of the operating segments based on the measures of revenues, cost of revenue and gross profit by central laboratory business,

in-hospital

business and pharma research and development services. Other than the information provided below, the CODM do not use any other measures by segments.

Summarized information by segments for the years ended December 31, 2018, 2019 and 2020 is as follows:


	For the year ended December 31, 2018
	Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB
Revenues:
Revenues from services		161,458			4,506			14,223			180,187
Revenues from sales of products		—			28,680			—			28,680


Total revenues		161,458			33,186			14,223			208,867


Cost of revenues:		(56,241	)		(13,120	)		(4,447	)		(73,808	)


Gross profit		105,217			20,066			9,776			135,059


	For the year ended December 31, 2019
	Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB
Revenues:
Revenues from services		276,254			(1,476	)		17,745			292,523
Revenues from sales of products		—			89,154			—			89,154


Total revenues		276,254			87,678			17,745			381,677


Cost of revenues:		(73,689	)		(29,506	)		(5,148	)		(108,343	)


Gross profit		202,565			58,172			12,597			273,334


	For the year ended December 31, 2020
	Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB			US$
Revenues:
Revenues from services		297,342			(847	)		14,689			311,184			47,691
Revenues from sales of products		—			118,719			—			118,719			18,194


Total revenues		297,342			117,872			14,689			429,903			65,885


Cost of revenues:		(73,960	)		(35,849	)		(6,172	)		(115,981	)		(17,775	)


Gross profit		223,382			82,023			8,517			313,922			48,110

Geographic

nformation

The analysis of the total long-lived assets excluding equity method investment, long-term investment and intangible assets by country was as follows:


	As of December 31,
	2019		2020
	RMB		RMB		US$
PRC		93,454		106,087		16,258
United States		6,814		28,415		4,355

		100,268		134,502		20,613

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Accounts Receivable, Net

12 Months Ended

Dec. 31, 2020

Receivables [Abstract]

Accounts Receivable, Net

4	ACCOUNTS RECEIVABLE, N E T


	As of December 31,
	2019			2020
	RMB			RMB			US$
Accounts receivable		101,934			112,433			17,231
Allowance for doubtful accounts		(13,112	)		(24,215	)		(3,711	)

		88,822			88,218			13,520

The following table presents the movement in the allowance for doubtful accounts:


	As of December 31,
	2018		2019			2020
	RMB		RMB			RMB			US$
Balance at the beginning of the year		920		1,827			13,112			2,010
Provisions		907		11,932			13,647			2,091
Write-offs		—		(647	)		(2,544	)		(390	)

Balance at the end of the year		1,827		13,112			24,215			3,711

Inventories

12 Months Ended

Dec. 31, 2020

Inventory Disclosure [Abstract]

Inventories

5	INVENTORIES


	As of December 31,
	2019		2020
	RMB		RMB		US$
Raw materials		24,877		27,637		4,236
Work in progress		19,182		24,849		3,808
Finished goods		14,057		15,535		2,381

		58,116		68,021		10,425

Prepayments And Other Current Assets

12 Months Ended

Dec. 31, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepayments And Other Current Assets

6	PREPAYMENTS AND OTHER CURRENT ASSETS

Prepayments and other current assets consist of the following:


	As of December 31,
	2019		2020
	RMB		RMB		US$
Deductible input VAT		37,254		34,157		5,235
Prepayments		14,217		14,773		2,267
Deferred IPO costs		9,686		—		—
Deposits		2,663		5,258		806
Interest receivables		7,194		2,016		309
Others		1,326		1,125		172

		72,340		57,329		8,789

Property And Equipment, Net

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Property And Equipment, Net

7	PROPERTY AND EQUIPMENT, NET

Property and equipment consist of the following:


	As of December 31,
	2019			2020
	RMB			RMB			US$
Machinery and laboratory equipment		120,478			153,589			23,537
Vehicles		2,296			2,588			397
Furniture and tools		7,541			10,085			1,546
Electronic equipment		26,708			32,526			4,985
Leasehold improvements		24,653			30,672			4,701
Construction in progress		674			1,089			167

		182,350			230,549			35,333
Accumulated depreciation		(93,036	)		(119,068	)		(18,248	)

		89,314			111,481			17,085

Depreciation expenses recognized for the years ended December 31, 2018, 2019 and 2020 were RMB24,498, RMB30,819 and RMB32,457 (US$4,974), respectively.

The Group entered into capital leases for certain laboratory equipment, electronic equipment and furniture and tools during the years ended December 31, 2019 and 2020.

The gross amounts of laboratory equipment, electronic equipment and furniture and tools under capital leases were

RMB14,794, RMB3,048 and RMB402,

respectively, as of December 31, 2019. The gross amount of laboratory equipment, electronic equipment and furniture and tools under capital leases were

RMB14,794 (US$2,267), RMB3,048 (US$467) and RMB402 (US$62), respectively, as of December 31, 2020.

The amounts of accumulated

depreciation on the assets under capital lease were RMB3,608 and RMB7,455 (US$1,143) as of December 31, 2019 and 2020, respectively.

As of December 31, 2020, future minimum capital lease payments were as follows:


	RMB			US$
For the years ending:
2021		5,111			783

Total minimum capital lease payments		5,111			783
Less: I nterest component		(295	)		(45	)

Present value of minimum capital lease payments		4,816			738

Intangible Assets, Net

12 Months Ended

Dec. 31, 2020

IntangibleAssets [Abstract]

Intangible Assets, Net

8	INTANGIBLE ASSETS, NET

Intangible assets consist of the following:


	As of December 31,
	2019			2020
	RMB			RMB			US$
Computer software		1,643			5,596			858
Accumulated amortization		(1,300	)		(2,139	)		(328	)

		343			3,457			530

Amortization expense

recognized for the years ended December 31, 2018, 2019 and 2020 were RMB181, RMB540 and RMB852 (US$131), respectively. As of December 31, 2020, estimated amortization expense

of the existing intangible assets for each of the next five years

was

RMB1,455, RMB1,347, RMB655, nil and nil, respectively.

Accrued Liabilities And Other Current Liabilities

12 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Accrued Liabilities And Other Current Liabilities

9	ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES

Accrued liabilities and other current liabilities consist of the following:


	As of December 31,
	2019		2020
	RMB		RMB		US$
Accrued payroll and welfare		25,366		39,497		6,053
Interests payable		593		711		109
Accrued reimbursement expenses		8,937		25,991		3,983
Professional service fees		9,707		5,695		873
Other taxes and surcharge		6,380		6,989		1,071
Others		3,076		4,765		731

		54,059		83,648		12,820

Borrowings

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Borrowings

10	BORROWINGS

Short-term borrowings

In November 2020, the Group entered into a

one-year

loan agreement with Industrial and Commercial Bank of China, pursuant to which the Group

may

borrow up to RMB5,000 with a fixed annual interest rate of 3.60%. The loan was intended for general working capital purposes. In December 2020, the Group drew down RMB5,000 (US$767).

As of December 31, 2020, the short-term borrowings also included RM

B2,370 (US$363)

RMB denominated loans from two third-party individuals with interest rate

of 5%

per annum. These loans are unsecured and repayable on demand.

Long-term borrowings

In July 2018, the Group entered into a banking facility agreement with SPD Silicon Valley Bank, pursuant to which the Group was entitled to borrow up to RMB80,000 at varying rates. The first RMB 10,000 of the facility had an annual interest rate of 6.5% and secured by accounts receivable of RMB34,807. The remaining RMB70,000 of the facility had an annual interest rate of 7.0%. The loan was intended for general working capital purposes. In 2018, the Group drew down RMB77,455 which

was

due in July 2020. In 2019, the Group early repaid the principal of RMB46,966.

The Group repaid the remaining principal of

RMB30,489 (US$4,637)

during the year ended December 31, 2020

In September 2019, the Group entered into a banking facility agreement for a term of two years with China Merchants Bank, pursuant to which the Group is entitled to borrow up to RMB33,000 at an interest rate separately agreed with the bank at each time of drawdown. The loan was intended for general working capital purposes. In December 2019, the Group drew down RMB14,720 at a fixed annual interest rate of 4.28%

which is due in September 2021, and the

Group repaid the principal of RMB1,500 (US$230). During the year ended December 31, 2020, the Group drew down an additional RMB

18,208 (US$2,790) at a fixed annual interest rate of 4.28% which is due in September 2021

To date the Group repaid RM

B1,780 (US$273)

in total principal.

In May 2018, the Group entered into two 3-year financing arrangements with Zhongguancun Technology Leasing Co., Ltd., which bore interest of an interest rate of

5.8% and were secured by certain machinery and laboratory equipment with an original cost of RMB32,405.

As of December 31, 2020, a total amount of RMB34,695 (US$5,317) repayable within twelve months was classified as “Current portion of long-term borrowings”.

Convertible Notes

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Convertible Notes

11	CONVERTIBLE NOTES

Series A+ convertible notes

In August 2015, the Group issued four convertible notes for an aggregate principal amount of US$7,900. In March 2016, the Group issued an additional convertible note for an aggregate principal amount of US$100 (collectively, the “Series A+ Notes”). The key features of the Series A+ Notes are as follows:

Interest

The Series A+ Notes bear interest of a simple interest rate of

15% annually on any unpaid principal.

Conversion features and rates

The Series A+ Notes are convertible into the Company’s Series B convertible preferred shares (“Series B Preferred Shares”) at the option of the holders upon completion of the sale of the Company’s Series B Preferred Shares (the “Series B Financing”). The number of the Series B Preferred Shares to be issued upon such conversion is equal to the principal and all accumulated but unpaid interest divided by the price per share of the equity securities equal to 95% of the price per share applicable to other investors participating in the Series B Financing.

Redemption

The outstanding principal and any accrued but unpaid interest will become due and payable in full at the earlier of i) the first anniversary of the issuance date

and

ii) upon the occurrence of any of events of default. The redemption date will be automatically extended by six months if the Group does not complete its Series B Financing by the first anniversary of the issuance date.

Series A+ supplementary convertible note

In August 2016, the Group issued a convertible note (“Series A+ Supplementary Note”) for a principal amount of US$8,000. The key features of the Series A+ Supplementary Note were identical to the Series A+ Notes, except the Series A Supplementary Notes accrued interest at 20% per annum and there was no discount on the per share conversion price.

Series B Convertible Note

In January 2017 and May 2017, the Group issued two convertible notes (“Series B Notes”) for an aggregate principal amount of US$17,000. The key features of the Series B Notes are as follows:

Interest

The Series B convertible notes bears simple interest at 9% on any unpaid principal.

Conversion Features and Rates

The Series B Notes is convertible into the Group’s Series C convertible preferred shares (“Series C Preferred Shares”) at the option of the holders upon completion of the sale of the Group’s Series C Preferred Shares (the “Series C Financing”). The number of the Series C Preferred Shares to be issued upon such conversion is equal to the principal and all accumulated but unpaid interest divided by the price per share of the equity securities equal to 95% of the price per share applicable to other investors participating in the Series C Financing.

Redemption

The outstanding principal and any accrued but unpaid interest will become due and payable in full at the earlier of i) the second anniversary of the issuance date

and

ii) upon the occurrence of any of events of default. The redemption date will be automatically extended by six months if the Group does not complete its Series C Financing by the second anniversary of the issuance date.

Accounting for the Series A+, Series A+ Supplementary and Series B Notes

The Series A+, Series A+ Supplementary and Series B Notes (collectively, the “Convertible Notes”) were recorded as liabilities carried at amortized cost. As the Convertible Notes will be share settled by a number of shares with a fair value equal to a fixed settlement amount, the settlement is not viewed as a conversion feature but as a redemption feature because the settlement amount does not vary with the share price. The

in-substance

redemption feature did not require bifurcation because it is clearly and closely related to the debt host. Since there is no embedded conversion feature, no beneficial conversion feature (“BCF”) was recorded. There were no other embedded derivatives that are required to be bifurcated.

Conversion

In January 2017, certain holders converted the Series A+ Notes and the Series A+ Supplementary Note with aggregate principal and accrued interest of RMB110,485 into 4,063,310 Series B Preferred Shares. No gain or loss was recognized from the conversion.

In January 2019, holder converted the Series B Notes with aggregate principal and accrued interest of RMB127,982 into 2,033,485 Series C Preferred Shares. No gain or loss was recognized from the conversion.

Repayment

In January 2017, the Group repaid the remaining Series A+ Note with the aggregate principal and unpaid interest of US$2,502.

Convertible Preferred Shares And Warrant

12 Months Ended

Dec. 31, 2020

Temporary Equity Disclosure [Abstract]

Convertible Preferred Shares And Warrant

12	CONVERTIBLE PREFERRED SHARES AND WARRANT

In June 2014, the Group issued 22,714,874 Series A redeemable convertible preferred shares (“Series A Preferred Shares”) to certain investors at US$0.24 per share for a total cash consideration of US$5,459.

In August 2015 and August 2016, the Group issued 10,599,927 Series A+ redeemable convertible preferred shares (“Series A+ Preferred Shares”) in aggregate to certain investors at US$1.26 per share for a total consideration of US$13,356. In January 2017, the Group issued additional 130,511 Series A+ Preferred Shares to an existing Series A+ Preferred Share holder at US$1.66 per share for total consideration of US$217.

In January 2017, the Group issued 7,020,059 Series B redeemable convertible preferred shares (“Series B Preferred Shares”) to certain investors at US$3.96 per share for a total consideration of US$27,812. Concurrently the Group issued 4,063,310 Series B Preferred Shares to certain investors upon conversion of the Group’s Series A+ convertible notes (

ote 11).

In May 2017 and December 2018, the Group issued 1,685,348 Series B Preferred Shares in aggregate at US$3.96 per share for a total consideration of US$6,677.

In January 2019, the Group issued 10,238,825 Series C redeemable convertible preferred shares (“Series C Preferred Shares”) to certain investors at US$9.39 per share for total consideration of US$96,144. Concurrently, the Group issued 2,033,485 Series C Preferred Shares to certain investors upon conversion of the Group’s Series B convertible notes (

ote 11). In October 2019, the Group issued 231,198 Series C Preferred Shares to several investors for a total consideration of US$2,171 at US$9.39 per share. In December 2019, the Group issued 21,299 Series C Preferred Shares to an investor for total consideration of US$200 at US$9.39 per share.

In January 2020, the Group issued 1,064,950 Series C redeemable convertible preferred shares (“Series C Preferred Shares”) to an investor upon the exercise of a Series C Warrant issued in January 2019 along with the issuance of Series C Preferred Shares. As of September 30, 2020, there were no warrants outstanding.

In January 2020, the Group issued 2,129,472 Series C+ redeemable convertible preferred shares (“Series C+ Preferred Shares”) at US$13.62 per share for a total consideration of US$29,000.

The number of issued and outstanding preferred shares and the issuance price per share presented in the financial statements were retrospectively adjusted upon the Company’s 2 for 1 Reverse Share Split. The Series A, Series A+, Series B, Series C and Series C+ Preferred Shares are collectively referred to as the “Preferred Shares”.

Dividends

Each holder of the Preferred Shares (collectively, the “Preferred Shareholders”) will be entitled to receive on a pari-passu basis,

non-cumulative

dividends when declared by the Board of Directors prior and in preference to ordinary shareholders. After the dividends to the relating to the Preferred Shares have been paid in full, each ordinary shareholder will be entitled to receive dividends payable in cash out of any remaining funds that are legally available when declared by the Board of Directors. No dividend or other distribution will be made or declared on the Company’s ordinary shares or any future series of preferred shares, unless and until an equivalent dividend is declared or paid on each outstanding Preferred Shares on an

as-if

converted basis.

No dividend was declared during the years presented.

Voting

Each Preferred Shareholder is entitled to the number of votes equal to the number of common shares into which such Preferred Shares could be converted at the voting date. Preferred shareholders will vote together with common shareholders, and not as a separate class of series, on all matters put before the shareholders.

Liquidation preference

In the event of any liquidation, dissolution or winding up of the Company or any deemed liquidation event defined as the liquidation, dissolution, acquisition, change of control or

winding-up

of the Company, the assets or surplus funds of the Company available for distribution will be distributed as follows:

The Series C preferred shareholders are entitled to receive an amount equal to 120% of the Series C Issue Price (as adjusted for share splits, share dividends or similar transactions), plus all accrued but unpaid dividends, in preference to any distribution to the holders of the Series A, Series A+ and Series B preferred shares and the common shareholders of the Company.

After the payment to the holders of Series C preferred shares, the Series B preferred shareholders are entitled to receive an amount equal to 150% of the Series B Issue Price (as adjusted for share splits, share dividends or similar transactions), plus all accrued but unpaid dividends, in preference to any distribution to the holders of the Series A, Series A+ preferred shares and the common shareholders of the Company.

After the payment to the holders of Series C and Series B preferred shares, the Series A+ and Series A preferred shareholders are entitled to receive an amount equal to 150% of the Series A+ and Series A Issue Price on pari-passu basis (as adjusted for share splits, share dividends or similar transactions), respectively, plus all accrued but unpaid dividend, in preference to any distribution to the holders of the common shareholders of the Company.

After payment has been made to the Preferred Shareholders in accordance with the above, the remaining assets of the Company available for distribution to shareholders will be distributed to on pari-passu basis among the holders of common shares and holders of Preferred Shares on as converted basis.

Conversion

Each Preferred Shareholder has the right, at the sole discretion of the holder, to convert at any time and from time to time, all or any portion of the Preferred Shares into common shares based on the then-effective conversion price. The initial conversion ratio shall be on a one for one basis, subject to certain anti-dilution adjustments.

All Preferred Shares are converted automatically into ordinary shares at the then effective applicable conversion price in the event of a Qualified IPO.

Redemption

The Series A Preferred Shares are redeemable at the holders’ option at any time beginning on the sixth anniversary of the original Series A issue date at the redemption price equal to 200% of the original issue price plus all accrued but unpaid dividends.

The Series A+ Preferred Shares are redeemable at the holders’ option at any time beginning on the sixth anniversary of the original Series A+ issue date at the redemption price equal to the original issue price (as adjusted for share splits, share dividends or similar transactions) plus 12% annual interest, and all accrued but unpaid dividends. The redemption price of the Series A Preferred Shares

was

modified to be the same as that of Series A+ Preferred Shares upon the issuance of Series A+ Preferred Shares.

The Series B Preferred Shares are redeemable at the holders’ option at any time beginning on the fifth anniversary of the original Series B issue date at the redemption price equal to the original issue price (as adjusted for share splits, share dividends or similar transactions) plus 12% annual interest, and all accrued but unpaid dividends. The redemption date of the Series A and A+ Preferred Shares w

modified to be the same as that of Series B Preferred Shares upon the issuance of Series B Preferred Shares.

The Series C Preferred Shares are redeemable at the holders’ option at any time beginning on the third anniversary of the original Series C issue date at the redemption price equal to the original issue price (as adjusted for share splits, share dividends or similar transactions) plus 12% annual interest, and all accrued but unpaid dividends.

Series C Warrant

Concurrent with the Series C financing the Group issued a Series C Warrant to one investors at nil consideration that allowed the holder to purchase

1,064,950 Series C convertible redeemable preferred shares at

exercise price of US$9.39

per share. On January 22, 2020, the holder of the Series C Warrant fully exercised its Series C Warrant.

Initial measurement and subsequent accounting for Preferred Shares

The Preferred Shares are initially classified as mezzanine equity in the consolidated balance sheets as these Preferred Shares may be redeemed at the option of the holders on or after an agreed upon date outside the sole control of the Group or upon a deemed liquidation event. All the Preferred Shares are initially measured at fair value. The holders of the Preferred Shares have the ability to convert the instrument into the Company’s ordinary shares. The Group evaluated the embedded conversion option in the Preferred Shares to determine if there were any embedded derivatives requiring bifurcation and to determine if there were any beneficial conversion features (“BCF”). There were no embedded derivatives that are required to be bifurcated. The conversion option of the Preferred Shares is not bifurcated because the conversion option is clearly and closely related to the host equity instrument. The contingent redemption options of the Preferred Shares are not bifurcated because the underlying ordinary shares are not net settable since the Preferred Shares were neither publicly traded nor readily convertible into cash.

No BCF was recognized for the Preferred Shares as the fair value per ordinary share at the commitment date was less than the respective most favorable conversion price. The Group determined the fair value of common shares with the assistance of an independent third-party appraiser.

The amendment to the redemption price for the Series A Preferred Shares upon the issuance of the Series A+ Preferred Shares and the amendment to the redemption date of the Series A and A+ Preferred Shares upon the issuance of the Series B Preferred Shares are accounted for as modifications as the fair values of Series A and A+ Preferred Shares immediately after the amendments were not significantly different from their respective fair values immediately before the amendment. The incremental fair value of Series A and A+ Preferred Shares as a result of the modifications was immaterial.

The Group elected to recognize the changes in redemption value as they occur and adjust the carrying amount of the Preferred Shares to equal the redemption value at each reporting period. Accretion charges were recorded as an increase to the net loss attributable to ordinary shareholders for the years presented.

The Preferred Shares were converted to ordinary shares immediately upon the completion of the Company’s IPO on June 12, 2020.

The changes in the carrying values of the Preferred Shares and the corresponding accretion in the periods presented are as follows:


Mezzanine equity	Series A			Series A+			Series B			Series C			Series C+			Total
	RMB			RMB			RMB			RMB			RMB			RMB

Balance as of December 31, 2017		48,985			108,764			382,893			—			—			540,642
Issuance of Series B preferred shares		—			—			2,000			—			—			2,000
Accretion of Preferred Shares		4,346			10,772			39,731			—			—			54,849
Repurchase of Preferred Shares		—			(1,373	)		—			—			—			(1,373	)


Balance as of December 31, 2018		53,331			118,163			424,624			—			—			596,118
Issuance of Series C preferred shares		—			—			—			766,127			—			766,127
Accretion of Preferred Shares		4,518			11,202			42,359			106,932			—			165,011
Repurchase of Preferred Shares		—			(223	)		—			—			—			(223	)


Balance as of December 31, 2019		57,849			129,142			466,983			873,059			—			1,527,033
Issuance of Series C preferred shares		—			—			—			—			201,118			201,118
Exercise of Series C Warrant		—			—			—			88,593			—			88,593
Accretion of Preferred Shares		2,068			5,074			19,167			28,061			10,318			64,688
Repurchase of Series C preferred shares		—			—			—			(3,727	)		—			(3,727	)
Conversion to ordinary shares		(59,917	)		(134,216	)		(486,150	)		(985,986	)		(211,436	)		(1,877,705	)


Balance as of December 31, 2020		—			—			—			—			—			—


Balance as of December 31, 2020 (US$)		—			—			—			—			—			—

Repurchase of preferred shares

The Group repurchased 124,985, 15,784, 4,438 Series A+ Preferred Shares, and 55,243 Series C Preferred Shares in December 2018, January 2019, October 2019 and May 2020 at consideration

of RMB1,500, RMB1,000, RMB294 and RMB3,500, respectively. The Group accounted for the difference

between the consideration paid and the fair value of the Series A+ Preferred Shares of nil, RMB611, RMB160, respectively, as compensation expenses relating to the employee shareholder of BRT Bio Tech Limited

for

the year ended December 31, 2019. The Group accounted for the difference

between the fair value and the carrying value of the Series

A+ repurchased of RMB127, RMB216

and

RMB84

respectively, as equity transactions in the statements of shareholders’ deficit for the year ended December 31, 2019. The Group accounted for the differences between the fair value and the carrying value of the Series C Preferred Shares repurchased of RMB227 as equity transactions in the statements of shareholders’ equity for the year ended December 31, 2020.

Initial measurement and subsequent accounting for warrant liability

The warrant is a freestanding instrument and recorded as a liability in accordance with ASC480. The warrant is initially recognized at fair value, with subsequent changes in fair value recorded in losses. The Series C Preferred Shares was initially recorded as mezzanine equity equal to the proceeds received of RMB766,127, net of the warrant fair value of RMB19,821 on January 31, 2019. The Company recognized a gain from the decrease in fair value of RMB3,503 (US$537) for the year ended December 31, 2020. The Company recognized a loss from the increase in fair value of RMB2,839 for the year ended December 31, 2019.

The fair value of the warrant is measured using significant unobservable (Level 3) inputs. The Group estimated the fair value of the warrant as of December 31, 2019 using the Black-Scholes option pricing model, based on the remaining contractual term of the warrants, risk-free interest rate and expected volatility of the price of the underlying Preferred Shares. The assumptions used, including the market value of the underlying Series C Preferred Shares and the expected volatility were subjective unobservable inputs. Significant increases (decreases) in the inputs used in the fair value measurement of the Level 3 warrant in isolation would result in a significant lower (higher) fair value measurement.

Share-Based Compensation

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

13	SHARE-BASED COMPENSATION

On June 20, 2014, the shareholders and Board of Directors (the “Board”) of the Company approved a resolution to reserve a total of 3,001,365

ordinary shares of the Company for the purpose of issuing share options awards to its eligible employees, officers or directors of the Group (the “Pre-IPO Plan”). On August 20, 2016, the shareholders and the Board approved a resolution to increase share option pool

to 3,690,599.

On April 19, 2018, the shareholders and the Board further approved a resolution to increase share option pool up

to 5,290,234

.Awards under the Pre-IPO Plan generally have vest over a period of 3 to 4 years and a contractual life of 10 years. The Company granted 652,723, 1,273,346 and 296,327 options under the Pre-IPO Plan for the years ended December 31, 2018, 2019 and 2020, respectively.

In January 2019, the shareholders and the Board of Directors of the Company approved a Management Share Incentive plan (“Management Plan”) for key executive management personnel. Under the Management Plan, the maximum number of ordinary shares reserved for issuance under is 5% of the total outstanding number of shares of the Company on an as converted and fully diluted basis (after taking into account the options granted under the plan). Awards under the Management Plan have vest over a period of 4 years and have a contractual life of 10 years. The Company granted 5,475,393 options under the Management Plan for the year ended December 31, 2020.

In May 2020, the shareholders and the Board of Directors of the Company approved an equity incentive plan (“2020 Plan”). Under the 2020 Plan, the Company is authorized to grant options, restricted shares and restricted share units for which the maximum aggregate number of ordinary shares which may be issued pursuant to all awards is

4,512,276

ordinary shares. Awards under the 2020 Plan have vest over a period of 4 years and have a contractual life of 10 years. The Company granted 4,848 restricted shares units under the 2020 Plan for the year ended December 31, 2020.

As of December 31, 2020, there were 847,415, 111,742 and 4,507,428 awards available for future grant for the Pre-IPO Plan, Management Plan and 2020 Plan, respectively.

Share options

The Board determines the exercise price, vesting and other conditions of individual awards and are subject to multiple service vesting periods. The options granted vests over various vesting schedules with no more than

four years.

Prior to the IPO, the Group determined the fair value of its share-based payment awards using the binomial option valuation model with assistance from an independent third-party appraiser. Upon completion of the IPO, the Group determined the fair value of share-based payment awards using the Black-Scholes model. The binomial and Black-Scholes models require subjective assumptions, including the grant date fair value of the ordinary shares, expected volatility, exercise multiple, risk-free rate and dividend yield. Prior to the IPO, the Group estimated grant date fair value of its ordinary shares with assistance from the third-party appraiser. Upon completion of the IPO, the Group used the grant date closing ADS price quoted on NASDAQ exchange to determine the fair value of its ordinary shares. For expected volatility, the Group referenced historical volatility of several comparable peer companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested options. The risk-free rate for periods within the contractual life of the options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on management’s expected dividend policy over the contractual life of the options.

The assumptions used to estimate the fair values of the share options, restricted shares and restricted share units granted are as follows:


	For the years ended December 31,
	2018	2019	2020
Risk-free interest rate	2.69% - 3.05%	1.63% - 2.41%	0.51% - 1.90%
Dividend yield	0%	0%	0%
Expected volatility range	46.0% - 47.8%	44.6% - 45.4%	44.9% - 49.3%
Exercise multiple	2.20	2.20 - 2.80	2.20
Contractual life	10 years	10 years	10 years
Fair market value per ordinary share as at valuation dates	US$2.32 - US$3.20	US$3.30 - US$9.41	US$9.41 - US$27.15

The Group recorded compensation costs using the straight-line method for employee award with only service condition and recorded compensation costs on a

tranche-by-tranche

basis for employee award with service condition and performance condition that has graded vesting schedule over the requisite service period. The share option awards are exercisable up to ten years from the grant date. The following table summarizes the share options activity for the years ended December 31, 2018, 2019 and 2020:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average Grant Date Fair Value		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
				US$ per option		US$ per option		Years		US$
Outstanding, January 1, 2018		3,248,211			0.0002		0.38		7.24		6,739

Granted		652,723			0.0002		2.77		—		—

Exercised		(818,554	)		0.0002		0.61		—		—
Forfeited		(32,212	)		0.0002		0.55		—		—

Outstanding, January 1, 2019		3,050,168			0.0002		0.97		7.14		9,744

Granted		1,273,346			2.8957		3.97		—		—
Exercised		(1,864,343	)		0.0002		0.30		—		—
Forfeited		(55,372	)		0.0002		2.90		—		—

Outstanding, January 1, 2020		2,403,799			1.5340		3.75		8.75		20,079

Granted		5,771,720			0.0002		26.75		—		—
Exercised		(233,440	)		0.0002		1.18		—		—
Forfeited		(121,650	)		0.0002		3.31		—		—

Outstanding, December 31, 2020		7,820,429			0.4717		21.28		9.10		176,963

Vested and expected to vest at December 31, 2020		7,820,429			0.4717		21.28		9.10		176,963

Exercisable at December 31, 2020		538,300			6.8495		2.76		7.48		8,748

The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date for those awards that had exercise price below the estimated fair value of the relevant ordinary shares.

The aggregate fair values of the equity awards vested during the years ended December 31, 2018, 2019 and 2020 were RM

B491, RMB9,485 and RMB3,580 (US$549),

respectively. As of December 31, 2020, there was total unrecognized employee share-based compensation expense of RMB972,698 (US$149,072) related to unvested options, which may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost is recognized over a weighted-average period

of 3.42 years.

Restricted shares units

The Board granted restricted share units

o one of the board members in June 2020. The Board determined vesting and other conditions of individual awards, which are subject to multiple service vesting periods. The restricted share units vest over a period of

two

years. The Group determined the fair value of the restricted share units using the grant date closing ADS price quoted on NASDAQ exchange. The Group recognized share-based compensation expenses using the straight-line method over the requisite service period, which is generally the vesting period of the restricted shares units. The restricted shares units are exercisable up to

ten years from the grant date.

The following table summarizes the restricted shares unit activities for the years ended December 31, 2018, 2019 and 2020:


	Number of shares		Weighted- Average purchase Price		Weighted- Average Grant Date Fair Value		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
			US$ per option		US$ per option		Years		US$
Outstanding, January 1, 2018		—		—		—		—		—

Outstanding, January 1, 2019		—		—		—		—		—

Outstanding, January 1, 2020		—		—		—		—		—

Granted		4,848		—		24.35		—		—

Outstanding, December 31, 2020		4,848		—		24.35		9.46		111,988

Vested and expected to vest at December 31, 2020		—		—		—		—		—

Exercisable at December 31, 2020		—		—		—		—		—

Restricted shares

Upon the issuance of the Series A Preferred Shares, the Founders entered into an arrangement with the Series A preferred shareholders,

whereby all ordinary shares of the Founders became subject to service and transfer restriction. Such shares are subject to repurchase by the Company at the price equal to the original purchase price paid by the Founders upon early termination of the requisite period of employment of the Founders. The restricted shares are subject to

a four-year service condition with 25% of the total shares shall be vested one year from the issuance of the Series A Preferred Shares and the remaining 75% of the total shares will be vested monthly in equal installment over the remaining requisite service period of 3 years. This arrangement is accounted for as a grant of restricted share awards subject to service vesting conditions.

On May 9, 2020 the Group’s shareholders and Board of Directors approved the Employee Share Incentive Plan No. 1 (the “ESIP No. 1”), pursuant to which the Group may issue up to 2,614,636 Class A ordinary shares to qualified employees at US$13.2 per share. The shares are subject to a three-year vesting period with

10%, 40% and 50%

of the shares vesting on the first, second and third anniversary of the Company’s IPO, respectively. The Group accounts for awards under the ESIP No. 1 as a grant of restricted share awards subject to vesting condition.

On June 25, 2020, the Group’s shareholders and Board of Directors approved the Employee Share Incentive Plan No. 2 (“the “ESIP No. 2”), pursuant to which the Group allowed qualified employees to purchase Class A ordinary shares at US$20.02 per share. Each qualified employee can subscribe up to RM

B2,000

worth of shares, depending on their position and length of service with the Group. The restricted shares are subject service vesting conditions and vest over a three-year period, with

10%, 40% and 50%

of the subscribed shares vesting on the first, second and third anniversary, respectively, from subscription date. This arrangement is accounted for as a grant of restricted share awards subject to service vesting conditions.

The following table summarizes the restricted share activities during the years ended December 31, 2018, 2019 and 2020:


	Number of shares			Weighted average grant date fair value
				US$ per share
Outstanding as of January 1, 2018		2,144,423			0.10
Vested		(2,144,423	)		0.10

Outstanding as of December 31, 2018		—			—

Outstanding as of December 31, 2019		—			—

Granted		743,955			8.74

Outstanding as of December 31, 2020		743,955			8.74

Prior to the IPO, the Group used the discounted cash flow method to determine the underlying equity value of the Company and adopted equity allocation model to determine the fair value of the restricted shares as of the dates of issuance. Upon completion of the IPO, the Group determined the fair value of the restricted share awards as the difference between the grant date closing ADS price quoted on NASDAQ exchange and the employees’ purchase price. The aggregate fair value of the restricted share awards granted during the year ended December 31, 2020 was

RMB42,540 (US$6,520). For the years ended December 31, 2018, 2019 and 2020, the Group recorded compensation expenses for the restricted shares of RMB1,226, nil and RMB1,671 (US$256), respectively.

Total share-based compensation expenses recognized for the years ended December 31, 2018, 2019 and 2020 were as follows:


	For the years ended December 31,
	2018		2019		2020
	RMB		RMB		RMB		US$

Cost of revenues		322		678		796		122
Research and development expenses		2,096		9,377		49,801		7,630
Selling and marketing expenses		547		1,235		3,457		530
General and administrative expenses		2,130		11,502		119,166		18,265


Total share-based compensation expenses		5,095		22,792		173,220		26,547

On August 19, 2019, the Group entered into an investment agreement with an employee to issue 85,196 Series C Preferred Shares at US$9.39 per share with a total consideration of US$800. The Group recognized the difference between the fair value of the preferred shares as of the commitment date and the issuance consideration of RMB463 as compensation expense for the year ended December 31, 2019.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

14	INCOME TAXES

PRC

Effective from January 1, 2008, the PRC’s statutory, Enterprise Income Tax (“EIT”) rate is 25%. In accordance with the implementation rules of EIT Law, a qualified “High and New Technology Enterprise” (“HNTE”) is eligible for a preferential tax rate of 15%. The HNTE certificate is effective for a period of three years. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant HNTE criteria before using the preferential rate. An entity could

re-apply

for the HNTE certificate when the prior certificate expires.

Guangzhou Burning Rock Dx Co., Ltd. was recognized as a qualified HNTE under the EIT Law by relevant government authorities in December 2019 and was entitled to the preferential rate of 15%. All other operating entities in the PRC are subject to the 25% EIT rate.

Cayman Islands

Under the current tax laws of Cayman Islands, the Company is not subject to tax on income or capital gains. Besides, upon payment of dividends by the Company to its shareholders, no Cayman Islands withholding tax will be imposed.

United States

As a result of the United States tax law amendments, the federal statutory income tax rate for the subsidiary in the US

was

21% for the year ended December 31, 2020. The subsidiary in the US was incorporated in the state of California, and

was

also subject to state income tax at a rate of approximately 8.8% for the year ended December 31, 2020.

Hong Kong

Under the Hong Kong tax laws, the subsidiary in Hong Kong is subject to the Hong Kong profit tax at a rate of 16.5% and it may be exempted from income tax on its foreign-derived

income. There are

no withholding taxes in Hong Kong on remittance of dividends.

The Group’s loss before income taxes consists of:


	For the years ended December 31,
	2018		2019		2020
	RMB		RMB		RMB			US$

PRC	(157,740	)	(150,495	)		(366,634	)		(56,189	)
Non-PRC	(19,757	)	(18,661	)		(40,601	)		(6,223	)

Total loss before income tax	(177,497	)	(169,156	)		(407,235	)		(62,412	)

For the years ended December 31, 2018, 2019 and 2020, the income generated by the subsidiary in Hong Kong was interest income derived from the bank that

was

exempted from Hong Kong profit tax. The Group did not recognize any current or deferred tax expense for the years presented.

Reconciliation between the income tax expenses computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax is as follows:


	For the years ended December 31,
	2018			2019			2020
	RMB			RMB			RMB			US$

Loss before income tax		(177,497	)		(169,156	)		(407,235	)		(62,412	)

Income tax benefits computed at PRC statutory rate (25%)		(44,374	)		(42,289	)		(101,809	)		(15,603	)
Effect of tax rate differential		5,052			10,474			10,375			1,590
Research and development super-deduction		(1,821	)		(4,712	)		(6,011	)		(921	)
Non-deductible expenses		5,394			10,629			54,255			8,315
Non-taxable income		(212	)		(1,412	)		(872	)		(134	)
Changes in valuation allowance		35,961			27,310			44,062			6,753


Income tax expenses		—			—			—			—

Deferred tax assets and liabilities

Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax balances as of December 31, 2019 and 2020 are as follows:


	For the years ended December 31,
	2019			2020
	RMB			RMB			US$

Deferred tax assets:
Accruals and reserves		3,913			9,205			1,410
Net operating loss carried forward		52,593			60,288			9,240
Government grants		222			39			6
Depreciation and amortization		685			681			104
Excessive education fee		967			654			100
Timing difference of research and development expense recognition		47,809			90,535			13,875
Timing difference of revenue recognition		10,160			6,425			985
Excessive donation expense carried forward		1,753			2,471			379

Gross deferred tax assets		118,102			170,298			26,099
Less: V aluation allowance		(118,102	)		(170,298	)		(26,099	)

Total deferred tax assets, net		—			—			—

As of December 31, 2019 and 2020, the Group had net operating losses of RMB210,376 and RMB241,152 (US$36,958), respectively, mainly deriving from entities in the PRC. The tax losses in the PRC can be carried forward for five years to offset future taxable profit, and the period was extended to ten years for entities that qualify as a HNTE in 2018 and thereafter. The tax losses of entities in the PRC will begin to expire in 202

, if not utilized.

Valuation allowances have been provided on the net deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. Realization of the net deferred tax assets is dependent on factors including future reversals of existing taxable temporary differences and adequate future income, exclusive of reversing deductible temporary differences, tax planning and tax loss or credit carry forwards. The Group evaluates the potential realization of deferred tax assets on an

entity-by-entity

basis. As of December 31, 2019 and 2020, valuation allowances were provided against deferred tax assets in entities where it was determined it was more likely than not that the benefits of the deferred tax assets will not be realized.

Unrecognized tax benefits

As of December 31, 2020 and for the year ended December 31, 2020, there was no significant impact from tax uncertainties on the Group’s consolidated financial position and result of operations. The Group did not record any interest and penalties related to an uncertain tax position for the year ended December 31, 2020. The Group does not expect the amount of unrecognized tax benefits would increase significantly in the next 12 months.

In general, the PRC tax authorities have up to five years to conduct examinations of the tax filings of the Company’s PRC subsidiaries, the VIE and the VIE’s subsidiaries. Accordingly, the PRC tax filings from 2014 through 2018 remain open to examination by the respective tax authorities. The Group may also be subject to the examinations of the tax filings in other jurisdictions, which are not material to the consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Loss Per Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Loss Per Share

15	LOSS PER SHARE

Basic and diluted loss per share for the years ended December 31, 2018, 2019 and 2020 are calculated as follows:


	For the years ended December 31,
	2018			2019			2020
	Ordinary shares						Class A						Class B
	RMB			RMB			RMB			US$			RMB			US$

Numerator:
Net loss attributable to Burning Rock Biotech Limited’s shareholder		(177,497	)		(169,156	)		(304,440	)		(46,658	)		(102,795	)		(15,754	)
Accretion of convertible preferred shares		(54,849	)		(165,011	)		(48,359	)		(7,411	)		(16,329	)		(2,503	)

Net loss attributable to ordinary shareholders		(232,346	)		(334,167	)		(352,799	)		(54,069	)		(119,124	)		(18,257	)


Denominator:
Weighted-average number of ordinary shares outstandin g		22,378,876			23,483,915			51,313,708			51,313,708			17,324,848			17,324,848
Effect of unvested restricted shares		—			—			(4,077 )			(4,077 )			—			—
Weighted-average number of ordinary shares outstanding – basic and diluted		22,378,876			23,483,915			51,309,631			51,309,631			17,324,848			17,324,848


Loss per share—basic and diluted		(10.38	)		(14.23	)		(6.88	)		(1.05	)		(6.88	)		(1.05	)

For the years ended December 31, 2018 and 2019, the computation of basic loss per share using the two-class method was not applicable as the Group was in a net loss position and the participating securities did not have contractual rights and obligations to share the losses of the Group. For the year ended December 31, 2020, the two-class method was applied to the outstanding Class A and Class B ordinary shares. The unvested restricted shares were excluded from the computation of weighted-average number or ordinary shares outstanding because the Group is in a loss position and the holder of the restricted shares do not have an obligation to fund losses of the Group. The effects of all outstanding Preferred Shares, the warrant and share options were excluded from the computation of diluted loss per share for the years ended December 31, 2018, 2019 and 2020 as their effects would be anti-dilutive.

Related Party Transactions

12 Months Ended

Dec. 31, 2020

Related Party Transactions

16	RELATED PARTY TRANSACTIONS

a)	Related Parties


Name of related parties		Relationship
Yusheng Han		Shareholder of a shareholder of the Company, Chief Executive Officer, director
Shaokun Chuai		Shareholder of a shareholder of the Company, Chief Operating Officer, director
Dan Zhou		Shareholder of a shareholder of the Company, management of the Group
BRT Bio Tech Limited		Controlling shareholder of the Company up to October 30, 2019
EaSuMed Holding Ltd.		Equity method investee

b)	The Group had the following related party balances at the end of the year:


	As of December 31,
	2019		2020
	RMB		RMB		US$
Yusheng Han		56,330		—		—
Shaokun Chuai		18,038		—		—
EaSuMed Holding Ltd.		—		212		32

Total amounts due from related parties		74,368		212		32

All the balances with related parties as of December 31, 2019 and 2020 were unsecured. All outstanding balances are repayable on demand unless otherwise disclosed. No allowance for doubtful accounts was recognized for the amount

due from related parties for the years ended December 31, 2018, 2019 and 2020.

c)	The Group had the following related party transactions:


	For the years ended December 31,
	2018		2019		2020
	RMB		RMB		RMB		US$
Service received from:
EaSuMed Holding Ltd.		1,225		806		770		118

Borrowings provided to:
Yusheng Han (i)		—		37,034		—		—
Shaokun Chuai (ii)		—		16,816		—		—
Dan Zhou		30		—		—		—

		30		53,850		—		—

Shares repurchased from:
BRT Bio Tech Limited (iii)		1,500		1,294		—		—

Interest income from:
Yusheng Han		—		1,295		176		27
Shaokun Chuai		—		591		295		45

		—		1,886		471		72

(i)	On March 29, 2019, the Group entered into a loan agreement with Yusheng Han with a principal amount of US$5,500 at the simple rate of 4.5% per annum. The loan which was fully repaid in February and March 2020.

(ii)	On March 28, 2019, the Group entered into a loan agreement with Shaokun Chuai with a principal amount of US$2,500 at the simple rate of 4.5% per annum. The loan which was fully repaid in May 2020.

(iii)

The Group repurchased 31,246 ordinary shares held by BRT Bio Tech Limited in 2018. The purchase consideration was RMB33,316. The Group repurchased 124,985 and 20,222 Series A+ Preferred shares held by BRT Bio Tech Limited in 2018 and 2019, respectively

consideration

of RMB1,500 and RMB1,294.

The Company recorded compensation expense of nil, RMB771 and nil during the year ended December 31, 2018, 2019 and 2020, respectively, for the amount exceeding the fair value of the ordinary and preferred shares at repurchase date.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

17	COMMITMENTS AND CONTINGENCIES

Operating lease commitments

As of December 31, 2020, future minimum payments under non-cancelable operating leases with initial terms in excess of one year consist of the following:


	RMB		US$
For the years ending:
2021		16,095		2,467
2022		15,647		2,398
2023		14,453		2,215
2024		7,288		1,117
2025		2,739		420

Total		56,222		8,617

Payments under operating leases are expensed on a straight-line basis over the periods of their respective leases. The Group’s lease arrangements have no renewal options, rent escalation clauses, restrictions or contingent rents and are all executed with third parties. For the years ended December 31, 2018, 2019 and 2020, total rental related expenses for all operating leases amounted to RMB8,689, RMB9,435 and RMB12,103 (US$1,855), respectively.

Capital expenditure commitments

The Group ha

capital expenditure commitments for the laboratory leasehold improvements and IT system improvements of RM

B1,540 (US$236) at December 31, 2020, which are scheduled to be paid within one year.

Contingencies

The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group’s business, financial position or results of operations.

Restricted Net Assets

12 Months Ended

Dec. 31, 2020

Restricted Net Assets [Abstract]

Restricted Net Assets

18	RESTRICTED NET ASSETS

The Company’s ability to pay dividends is primarily dependent on the Company receiving distributions of funds from its subsidiary, the VIE and subsidiary of the VIE. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s PRC subsidiaries, the VIE and subsidiary of the VIE only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Company’s subsidiaries, the VIE and VIE’s subsidiaries.

In accordance with the Regulations on Enterprises with Foreign Investment of China and the articles of association of the Company’s PRC subsidiary, a foreign invested enterprise established in the PRC, is required to provide certain statutory reserves, namely the general reserve fund, enterprise expansion fund and staff welfare and bonus fund, all of which are appropriated from net profit as reported in its PRC statutory accounts. A foreign-invested enterprise is required to allocate at least

of its annual after tax profit to the general reserve fund until such reserve has reached

50%

of its registered capital based on the enterprise’s PRC statutory accounts. Appropriations to the enterprise expansion fund and staff welfare and bonus fund are at the discretion of the board of directors for all foreign-invested enterprises. These reserves can only be used for specific purposes and are not distributable as cash dividends. The WFOE was established as a foreign-invested enterprise and, therefore, is subject to the above mandated restrictions on distributable profits. No appropriations were made to statutory reserves by the WFOE during all periods presented due to losses incurred.

Additionally, in accordance with the Company Law of the PRC, a domestic enterprise is required to provide statutory surplus fund at least

10%

of its annual after - tax profits until such statutory surplus fund has reached

50%

of its registered capital based on the enterprise’s PRC statutory financial statements. A domestic enterprise is also required to provide discretionary surplus fund, at the discretion of the board of directors from the net profits reported in the enterprise’s PRC statutory financial statements. The aforementioned reserve funds can only be used for specific purposes and are not distributable as cash dividends. No appropriations were made to statutory reserves by the Company’s PRC subsidiary as a domestic enterprise, the VIE and the VIE’s subsidiaries during all periods presented due to losses incurred.

Foreign exchange and other regulations in the PRC may further restrict the Group’s VIE from transferring funds to the Company in the form of dividends, loans and advances. Amounts restricted include paid-in capital and statutory reserves of the Group’s PRC subsidiaries and the equity of the VIE and its subsidiaries, as determined pursuant to PRC generally accepted accounting principles. As a result of these PRC laws and regulations, the PRC entities are restricted from transferring a portion of their net assets to the Company. As of December 31, 2019 and 2020, restricted net assets the Company’s PRC subsidiaries, the VIE and the VIE’s subsidiaries were RMB360,486 and RMB502,218 (US$76,968), respectively.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Basis of presentation

The accompany consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”).

Certain prior year amounts in the consolidated statements of comprehensive loss have been reclassified to conform to the current year presentation.

Principles of Consolidation

Principles of consolidation

Use of estimates

Foreign currency translation

Foreign Currency Matters

re-measured

at the exchange rates prevailing at the balance sheet date.

Non-monetary

items that are measured in terms of historical costs in foreign currency are

re-measured

using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.

Convenience translation

Cash and cash equivalents

Restricted cash

Restricted cash primarily represent deposits restricted in designated bank accounts for specific uses in relation to certain government grants received.

In November 2016, the FASB issued Accounting Standard Update (“ASU”)

No. 2016-18,

Statement of Cash Flows (Topic 230): Restricted Cash

Accounts receivable and allowance for doubtful accounts

Short-term investment

Short-term

investment

Fair value measurements

The Group applies ASC 820,

Fair Value Measurements and Disclosures

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets

Level 2 - Include other inputs that are directly or indirectly observable in the marketplace

Level 3 - Unobservable inputs which are supported by little or no market activity

On January 22, 2020, the holder of the Series C convertible redeemable preferred shares warrants (the “Series C Warrant”) exercised its Series C

Warrant and purchased

1,064,950 Series C convertible redeemable preferred shares (

ote 12). The Group recognized a gain from the

decrease in warrant fair value

of RMB3,503 (US$537) for the year ended December 31, 2020. The Group recognized a loss from the increase in fair value of RMB2,839 for the year ended December 31, 2019.

The Group records fair value change of the warrant as a component of non-operating income (expense) in the consolidated statement of comprehensive loss.


Financial instrument	Valuation technique	Unobservable input	Estimation
Warrant liability	Black-Scholes option pricing model	Volatility for Black-Scholes option pricing model		45	%
		Market value of the underlying Series C Preferred Shares	US$	12.08

The following table presents a reconciliation of all financial instruments measured at fair value on a recurring basis using Level 3 unobservable inputs:


	Warrant liability
	RMB
Balance as of December 31, 2019		23,503
Fair value change		(3,503	)
Foreign exchange translation		(260	)
Exercise of Series C Warrant ( N ote 12)		(19,740	)

Balance as of December 31, 2020		—

The amount of total gain for the year ended December 31, 2020 included in losses (RMB)		3,503
The amount of total gain for the year ended December 31, 2020 included in losses (US$ )		537

The Group had no financial assets and liabilities measured and recorded at fair value

on a non-recurring basis as of December 31, 2019 and 2020.

Inventories

Equity method investment

Equity method investments represent investments in entities in which the Group can exercise significant influence but does not own a majority equity interest or control

and

are accounted for using the equity method of accounting in accordance with ASC Subtopic

323-10,

Investments-Equity Method and Joint Ventures: Overall

323-10.

An impairment loss on the equity method investments is recognized in the consolidated statements of comprehensive loss when the decline in value is determined to be other-than-temporary.

In January 2017, the Group acquired for 20.29% equity interest in EaSuMed Holding Ltd.

an amount of US$363. In October 2020, additional shares were allotted to the Group from EaSuMed Holding Ltd. and therefore the Group held

from equity method investment of RMB422, RMB230 and RMB275 (US$42) for the years ended December 31, 2018, 2019 and 2020, respectively. No impairment loss was recognized for the years presented.

Property and equipment, net

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:


Category		Estimated Useful Life
Machinery and laboratory equipment		5 years
Vehicles		6 years
Furniture and tools		5 years
Electronic equipment		3 years
Leasehold improvements		Lesser of lease terms or estimated useful lives of the assets

Intangible assets, net


Category		Estimated Useful Life
Computer software		3 years

The Group does not have any indefinite-lived intangible assets.

Impairment of long-lived assets

No impairment loss was recorded for the years ended December 31, 2018, 2019 and 2020.

Segment reporting

In accordance with ASC 280,

Segment Reporting

in-hospital

business and pharma research and development services. Substantially all of the Group’s revenues are derived from within the PRC.

Revenue recognition

Revenue from central laboratory business

of nil, RMB14,723 and RMB11,900 (US$1,824)

for the years ended December 31, 2018, 2019 and 2020, respectively.

Revenue from

in-hospital

business

Revenue from

in-hospital

Revenue from pharma research and development services

Contract assets and liabilities

)

for the years ended December 31, 2018, 2019 and 2020, respectively.

Value added taxes and related surcharges

the previous applicable VAT tax rates of

17% were adjusted to 16% and further adjusted to 13% beginning

April 2019.

Research and development expenses

Government subsidies

Leases

The Group classifies leases as either operating or capital leases at inception date. The Group assesses a lease to be a capital lease if any of the following conditions exists: a) ownership

non-cancelable

Comprehensive loss

Income taxes

The Group follows the liability method of accounting for income taxes in accordance with ASC 740,

Income Taxes

Share-based compensation

The Group applies ASC 718,

Compensation — Stock Compensation

paid-in

capital. For employee award with service condition and performance condition that has graded vesting schedule, the Group record compensation costs on a

tranche-by-tranche

basis, with a corresponding impact reflected in additional

paid-in

capital. The Group early adopted ASU

No. 2016-09

Compensation-Stock Compensation (Topic 718): Improvement to Employee Share-based Payment Accounting (“ASU

2016-09”)

and accounts for forfeitures as they occur.

Loss per share

In accordance with ASC 260,

Earnings Per Share

, basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the

two-class

method. Under the

two-class

if-converted

two-class

method is not applicable as the Company is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Company.

Employee defined contribution plan

Modification of redeemable convertible preferred shares

Concentration of credit risk

As of December 31 2020, the Group had R

Concentration of suppliers

Business and economic risk

Currency convertibility risk

Foreign currency exchange rate risk

From July 21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For US$ against RMB, there was appreciation

of approximately 5.7% and 1.3%, depreciation of approximately 6.3% in the years ended December 31, 2018, 2019 and 2020 respectively.

Reverse share split

2-for-1

the

related per share amounts contained in the financial statements have been retroactively adjusted to reflect the Reverse Share Split for all periods presented.

Recently issued accounting pronouncements

In February 2016, the FASB issued ASU

No. 2016-02

(“ASU

2016-02”),

Leases

No. 2018-10

(“ASU

2018-10”),

Codification Improvements to Topic 842, Leases

, which clarifies certain aspects of the guidance issued in ASU

2016-02;

and ASU

No. 2018-11

(“ASU

2018-11”),

Leases (Topic 842): Targeted Improvements

No. 2019-10,

Financial

Instruments - Credit Losses

(Topic 326),

Derivatives and Hedging (Topic 815), and Leases (Topic 842), Effective Dates

(“ASU

2019-10”),

Early adoption is permitted. The Group plans to early adopt the new lease standard and the Group

expects that applying the ASU

2016-02

would materially increase the assets and liabilities due to the recognition of

right-of-use

assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows.

In June 2016, the FASB issued ASU

No. 2016-13,

Financial Instruments - Credit Losses

(Topic 326): Measurement of Credit Losses on Financial Instruments

(“ASU

2016-13”).

ASU

2016-13

2019-10,

which extends the adoption date for certain registrants. The amendments in ASU

2016-13

are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023.

The Group plans to early adopt the credit losses standard and expects that applying ASU 2016-13 would increase the allowance accounts receivable and contract assets.

In December 2019, the FASB issued ASU 2019-12,

Simplifying the Accounting for Income Taxes

In January 2020, the FASB issued ASU 2020-01,

Clarifying the interactions between Topic 321, Topic 323 and Topic 815.

Organization and Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of subsidiaries, VIE and VIE's subsidiaries

As of December 31, 2020, the Company’s principal subsidiaries, VIE and VIE’s subsidiaries are as follows:


Entity	Date of incorporation	Place of incorporation	Percentage of legal ownership by the Company	Principalactivities
Subsidiaries
BR Hong Kong Limited	April 1, 2014	Hong Kong	100%	Investment holding

Beijing Burning Rock Biotech Co., Ltd. (the “WFOE”)	June 13, 2014	PRC	100%	Trading
Burning Rock Biotechnology (Shanghai) Co., Ltd.	July 4, 2016	PRC	100%	Research and development

VIE
Burning Rock (Beijing) Biotechnology Co., Ltd.	January 7, 2014	PRC	Nil	Holding

VIE’s subsidiaries
Guangzhou Burning Rock Dx Co., Ltd.	March 18, 2014	PRC	Nil	Cancer therapy selection test and sales of reagent kits
Guangzhou Burning Rock Medical Equipment Co., Ltd.	January 6, 2015	PRC	Nil	Facilitation of laboratory equipment sales

Guangzhou Burning Rock Biotechnology Co., Ltd.	January 23, 2018	PRC	Nil	Cancer therapy selection test and sales of reagent kits

Summary of financial information of VIE and VIE's subsidiaries

The following table sets forth the assets and liabilities of the VIE and subsidiaries of the VIE included in the Group’s consolidated balance sheets:


	As of December 31,
	2019		2020
	RMB		RMB		US$

Cash and cash equivalents		28,102		149,736		22,948
Restricted cash		4,009		263		40
Accounts receivable (net of allowances of RMB12,665 and RMB23,983 (US$3,676) as of December 31, 2019 and 2020, respectively)		88,555		88,217		13,520
Contract assets		909		22,534		3,453
Amounts due from related parities		2,052		212		32
Inter-company receivables*		7,232		8,432		1,292
Inventories		49,662		61,374		9,406
Prepayments and other current assets		15,931		17,548		2,692

Total current assets		196,452		348,316		53,383

Property and equipment, net		33,246		32,342		4,957
Intangible assets, net		91		77		12
Other non-current assets		3,171		5,797		888

Total non-current assets		36,508		38,216		5,857

TOTAL ASSETS		232,960		386,532		59,240


Accounts payable		10,068		26,871		4,118
Deferred revenue		49,539		74,402		11,403
Inter-company payables*		273,772		495,526		75,943
Capital lease obligations, current		4,893		4,816		738
Accrued liabilities and other current liabilities		38,422		54,271		8,317
Customer deposits		4,104		1,120		172
Short-term borrowings		2,370		7,370		1,130
Current portion of long-term borrowings		30,987		266		41

Total current liabilities		414,155		664,642		101,862

Deferred government grant		991		263		40
Capital lease obligations		4,816		—		—
Long-term borrowings		266		—		—

Total non-current liabilities		6,073		263		40

TOTAL LIABILITIES		420,228		664,905		101,902

*	Inter-company receivables/payables represent balances of VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries.

Summary of operations and comprehensive loss statements of VIE and VIE's subsidiaries

The table sets forth the results of operations of the VIE and subsidiaries of the VIE included in the Group’s consolidated statements of comprehensive loss:


	For the years ended December 31,
	2018			2019			2020
	RMB			RMB			RMB			US$

Revenues		204,310			381,460			432,142			66,229
Net loss		(93,455	)		(72,015	)		(244,765	)		(37,510	)

Summary of cash flow statement of VIE and VIE's subsidiaries

The table sets forth the cash flows of the VIE and subsidiaries of the VIE included in the Group’s consolidated statements of cash flows:


	For the years ended December 31,
	2018			2019			2020
	RMB			RMB			RMB			US$

Net cash (used in) generated from operating activitie s		(44,153	)		(4,993	)		158,563			24,301
Net cash used in investing activities		(7,908	)		(56,052	)		(9,795	)		(1,501	)
Net cash generated from (used in) financing activities		79,261			34,540			(30,880	)		(4,733	)

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of Fair Value of Warrant Liability Measured on Recurring Basis Using Significant Unobservable Inputs


Financial instrument	Valuation technique	Unobservable input	Estimation
Warrant liability	Black-Scholes option pricing model	Volatility for Black-Scholes option pricing model		45	%
		Market value of the underlying Series C Preferred Shares	US$	12.08

Summary of Warrants Measured at Fair Value on a Recurring Basis

Therefore, there were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2020.


	Warrant liability
	RMB
Balance as of December 31, 2019		23,503
Fair value change		(3,503	)
Foreign exchange translation		(260	)
Exercise of Series C Warrant ( N ote 12)		(19,740	)

Balance as of December 31, 2020		—

The amount of total gain for the year ended December 31, 2020 included in losses (RMB)		3,503
The amount of total gain for the year ended December 31, 2020 included in losses (US$ )		537

Summary of Property and Equipment Estimated Useful Lives

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:


Category		Estimated Useful Life
Machinery and laboratory equipment		5 years
Vehicles		6 years
Furniture and tools		5 years
Electronic equipment		3 years
Leasehold improvements		Lesser of lease terms or estimated useful lives of the assets

Summary of Intangible Assets Estimated Useful Livess

The estimated useful life for the intangible assets is as follows:


Category		Estimated Useful Life
Computer software		3 years

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Summary of Segment Reporting Information

Summarized information by segments for the years ended December 31, 2018, 2019 and 2020 is as follows:


	For the year ended December 31, 2018
	Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB
Revenues:
Revenues from services		161,458			4,506			14,223			180,187
Revenues from sales of products		—			28,680			—			28,680


Total revenues		161,458			33,186			14,223			208,867


Cost of revenues:		(56,241	)		(13,120	)		(4,447	)		(73,808	)


Gross profit		105,217			20,066			9,776			135,059


	For the year ended December 31, 2019
	Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB
Revenues:
Revenues from services		276,254			(1,476	)		17,745			292,523
Revenues from sales of products		—			89,154			—			89,154


Total revenues		276,254			87,678			17,745			381,677


Cost of revenues:		(73,689	)		(29,506	)		(5,148	)		(108,343	)


Gross profit		202,565			58,172			12,597			273,334


	For the year ended December 31, 2020
	Central laboratory business			In-hospital business			Pharma research and development services			Total
	RMB			RMB			RMB			RMB			US$
Revenues:
Revenues from services		297,342			(847	)		14,689			311,184			47,691
Revenues from sales of products		—			118,719			—			118,719			18,194


Total revenues		297,342			117,872			14,689			429,903			65,885


Cost of revenues:		(73,960	)		(35,849	)		(6,172	)		(115,981	)		(17,775	)


Gross profit		223,382			82,023			8,517			313,922			48,110

Summary of Total Long Lived Assets By Geographical Location

The analysis of the total long-lived assets excluding equity method investment, long-term investment and intangible assets by country was as follows:


	As of December 31,
	2019		2020
	RMB		RMB		US$
PRC		93,454		106,087		16,258
United States		6,814		28,415		4,355

		100,268		134,502		20,613

Accounts Receivable, Net (Tables)

12 Months Ended

Dec. 31, 2020

Receivables [Abstract]

Summary of Account Receivable


	As of December 31,
	2019			2020
	RMB			RMB			US$
Accounts receivable		101,934			112,433			17,231
Allowance for doubtful accounts		(13,112	)		(24,215	)		(3,711	)

		88,822			88,218			13,520

Summary of Movement in the Allowances for Doubtful Accounts

The following table presents the movement in the allowance for doubtful accounts:


	As of December 31,
	2018		2019			2020
	RMB		RMB			RMB			US$
Balance at the beginning of the year		920		1,827			13,112			2,010
Provisions		907		11,932			13,647			2,091
Write-offs		—		(647	)		(2,544	)		(390	)

Balance at the end of the year		1,827		13,112			24,215			3,711

Inventories (Tables)

12 Months Ended

Dec. 31, 2020

Inventory, Work in Process and Raw Materials [Abstract]

Summary of Inventories


	As of December 31,
	2019		2020
	RMB		RMB		US$
Raw materials		24,877		27,637		4,236
Work in progress		19,182		24,849		3,808
Finished goods		14,057		15,535		2,381

		58,116		68,021		10,425

Prepayments And Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2020

Deferred Costs Capitalized Prepaid And Other Assets [Abstract]

Summary of Prepayments and Other Current Assets

Prepayments and other current assets consist of the following:


	As of December 31,
	2019		2020
	RMB		RMB		US$
Deductible input VAT		37,254		34,157		5,235
Prepayments		14,217		14,773		2,267
Deferred IPO costs		9,686		—		—
Deposits		2,663		5,258		806
Interest receivables		7,194		2,016		309
Others		1,326		1,125		172

		72,340		57,329		8,789

Property And Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consist of the following:


	As of December 31,
	2019			2020
	RMB			RMB			US$
Machinery and laboratory equipment		120,478			153,589			23,537
Vehicles		2,296			2,588			397
Furniture and tools		7,541			10,085			1,546
Electronic equipment		26,708			32,526			4,985
Leasehold improvements		24,653			30,672			4,701
Construction in progress		674			1,089			167

		182,350			230,549			35,333
Accumulated depreciation		(93,036	)		(119,068	)		(18,248	)

		89,314			111,481			17,085

Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]

As of December 31, 2020, future minimum capital lease payments were as follows:


	RMB			US$
For the years ending:
2021		5,111			783

Total minimum capital lease payments		5,111			783
Less: I nterest component		(295	)		(45	)

Present value of minimum capital lease payments		4,816			738

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2020

IntangibleAssets [Abstract]

Summary of Intangible Assets

Intangible assets consist of the following:


	As of December 31,
	2019			2020
	RMB			RMB			US$
Computer software		1,643			5,596			858
Accumulated amortization		(1,300	)		(2,139	)		(328	)

		343			3,457			530

Accrued Liabilities And Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Summary of Accrued Liabilities and Other Current Liabilities

Accrued liabilities and other current liabilities consist of the following:


	As of December 31,
	2019		2020
	RMB		RMB		US$
Accrued payroll and welfare		25,366		39,497		6,053
Interests payable		593		711		109
Accrued reimbursement expenses		8,937		25,991		3,983
Professional service fees		9,707		5,695		873
Other taxes and surcharge		6,380		6,989		1,071
Others		3,076		4,765		731

		54,059		83,648		12,820

Convertible Preferred Shares And Warrant (Tables)

12 Months Ended

Dec. 31, 2020

Temporary Equity Disclosure [Abstract]

Schedule of change in carring value of preferred shares

The changes in the carrying values of the Preferred Shares and the corresponding accretion in the periods presented are as follows:


Mezzanine equity	Series A			Series A+			Series B			Series C			Series C+			Total
	RMB			RMB			RMB			RMB			RMB			RMB

Balance as of December 31, 2017		48,985			108,764			382,893			—			—			540,642
Issuance of Series B preferred shares		—			—			2,000			—			—			2,000
Accretion of Preferred Shares		4,346			10,772			39,731			—			—			54,849
Repurchase of Preferred Shares		—			(1,373	)		—			—			—			(1,373	)


Balance as of December 31, 2018		53,331			118,163			424,624			—			—			596,118
Issuance of Series C preferred shares		—			—			—			766,127			—			766,127
Accretion of Preferred Shares		4,518			11,202			42,359			106,932			—			165,011
Repurchase of Preferred Shares		—			(223	)		—			—			—			(223	)


Balance as of December 31, 2019		57,849			129,142			466,983			873,059			—			1,527,033
Issuance of Series C preferred shares		—			—			—			—			201,118			201,118
Exercise of Series C Warrant		—			—			—			88,593			—			88,593
Accretion of Preferred Shares		2,068			5,074			19,167			28,061			10,318			64,688
Repurchase of Series C preferred shares		—			—			—			(3,727	)		—			(3,727	)
Conversion to ordinary shares		(59,917	)		(134,216	)		(486,150	)		(985,986	)		(211,436	)		(1,877,705	)


Balance as of December 31, 2020		—			—			—			—			—			—


Balance as of December 31, 2020 (US$)		—			—			—			—			—			—

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Summary of share options activity

The following table summarizes the share options activity for the years ended December 31, 2018, 2019 and 2020:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average Grant Date Fair Value		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
				US$ per option		US$ per option		Years		US$
Outstanding, January 1, 2018		3,248,211			0.0002		0.38		7.24		6,739

Granted		652,723			0.0002		2.77		—		—

Exercised		(818,554	)		0.0002		0.61		—		—
Forfeited		(32,212	)		0.0002		0.55		—		—

Outstanding, January 1, 2019		3,050,168			0.0002		0.97		7.14		9,744

Granted		1,273,346			2.8957		3.97		—		—
Exercised		(1,864,343	)		0.0002		0.30		—		—
Forfeited		(55,372	)		0.0002		2.90		—		—

Outstanding, January 1, 2020		2,403,799			1.5340		3.75		8.75		20,079

Granted		5,771,720			0.0002		26.75		—		—
Exercised		(233,440	)		0.0002		1.18		—		—
Forfeited		(121,650	)		0.0002		3.31		—		—

Outstanding, December 31, 2020		7,820,429			0.4717		21.28		9.10		176,963

Vested and expected to vest at December 31, 2020		7,820,429			0.4717		21.28		9.10		176,963

Exercisable at December 31, 2020		538,300			6.8495		2.76		7.48		8,748

Summary of stock options valuation assumptions

The assumptions used to estimate the fair values of the share options, restricted shares and restricted share units granted are as follows:


	For the years ended December 31,
	2018	2019	2020
Risk-free interest rate	2.69% - 3.05%	1.63% - 2.41%	0.51% - 1.90%
Dividend yield	0%	0%	0%
Expected volatility range	46.0% - 47.8%	44.6% - 45.4%	44.9% - 49.3%
Exercise multiple	2.20	2.20 - 2.80	2.20
Contractual life	10 years	10 years	10 years
Fair market value per ordinary share as at valuation dates	US$2.32 - US$3.20	US$3.30 - US$9.41	US$9.41 - US$27.15

Summary of restricted shares activities

The following table summarizes the restricted share activities during the years ended December 31, 2018, 2019 and 2020:


	Number of shares			Weighted average grant date fair value
				US$ per share
Outstanding as of January 1, 2018		2,144,423			0.10
Vested		(2,144,423	)		0.10

Outstanding as of December 31, 2018		—			—

Outstanding as of December 31, 2019		—			—

Granted		743,955			8.74

Outstanding as of December 31, 2020		743,955			8.74

Summary of share-based compensation expenses

Total share-based compensation expenses recognized for the years ended December 31, 2018, 2019 and 2020 were as follows:


	For the years ended December 31,
	2018		2019		2020
	RMB		RMB		RMB		US$

Cost of revenues		322		678		796		122
Research and development expenses		2,096		9,377		49,801		7,630
Selling and marketing expenses		547		1,235		3,457		530
General and administrative expenses		2,130		11,502		119,166		18,265


Total share-based compensation expenses		5,095		22,792		173,220		26,547

Restricted Stock Units (RSUs) [Member]

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]

Summary of share options activity


	Number of shares		Weighted- Average purchase Price		Weighted- Average Grant Date Fair Value		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
			US$ per option		US$ per option		Years		US$
Outstanding, January 1, 2018		—		—		—		—		—

Outstanding, January 1, 2019		—		—		—		—		—

Outstanding, January 1, 2020		—		—		—		—		—

Granted		4,848		—		24.35		—		—

Outstanding, December 31, 2020		4,848		—		24.35		9.46		111,988

Vested and expected to vest at December 31, 2020		—		—		—		—		—

Exercisable at December 31, 2020		—		—		—		—		—

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Summary of Group's Loss before Income Taxes

The Group’s loss before income taxes consists of:


	For the years ended December 31,
	2018		2019		2020
	RMB		RMB		RMB			US$

PRC	(157,740	)	(150,495	)		(366,634	)		(56,189	)
Non-PRC	(19,757	)	(18,661	)		(40,601	)		(6,223	)

Total loss before income tax	(177,497	)	(169,156	)		(407,235	)		(62,412	)

Summary of Reconciliation of Effective Tax rate and Statutory Income Tax rate

Reconciliation between the income tax expenses computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax is as follows:


	For the years ended December 31,
	2018			2019			2020
	RMB			RMB			RMB			US$

Loss before income tax		(177,497	)		(169,156	)		(407,235	)		(62,412	)

Income tax benefits computed at PRC statutory rate (25%)		(44,374	)		(42,289	)		(101,809	)		(15,603	)
Effect of tax rate differential		5,052			10,474			10,375			1,590
Research and development super-deduction		(1,821	)		(4,712	)		(6,011	)		(921	)
Non-deductible expenses		5,394			10,629			54,255			8,315
Non-taxable income		(212	)		(1,412	)		(872	)		(134	)
Changes in valuation allowance		35,961			27,310			44,062			6,753


Income tax expenses		—			—			—			—

Summary of Principle Components of Deferred Tax Assets

The tax effects of temporary differences that give rise to the deferred tax balances as of December 31, 2019 and 2020 are as follows:


	For the years ended December 31,
	2019			2020
	RMB			RMB			US$

Deferred tax assets:
Accruals and reserves		3,913			9,205			1,410
Net operating loss carried forward		52,593			60,288			9,240
Government grants		222			39			6
Depreciation and amortization		685			681			104
Excessive education fee		967			654			100
Timing difference of research and development expense recognition		47,809			90,535			13,875
Timing difference of revenue recognition		10,160			6,425			985
Excessive donation expense carried forward		1,753			2,471			379

Gross deferred tax assets		118,102			170,298			26,099
Less: V aluation allowance		(118,102	)		(170,298	)		(26,099	)

Total deferred tax assets, net		—			—			—

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted loss per share for the years ended December 31, 2018, 2019 and 2020 are calculated as follows:


	For the years ended December 31,
	2018			2019			2020
	Ordinary shares						Class A						Class B
	RMB			RMB			RMB			US$			RMB			US$

Numerator:
Net loss attributable to Burning Rock Biotech Limited’s shareholder		(177,497	)		(169,156	)		(304,440	)		(46,658	)		(102,795	)		(15,754	)
Accretion of convertible preferred shares		(54,849	)		(165,011	)		(48,359	)		(7,411	)		(16,329	)		(2,503	)

Net loss attributable to ordinary shareholders		(232,346	)		(334,167	)		(352,799	)		(54,069	)		(119,124	)		(18,257	)


Denominator:
Weighted-average number of ordinary shares outstandin g		22,378,876			23,483,915			51,313,708			51,313,708			17,324,848			17,324,848
Effect of unvested restricted shares		—			—			(4,077 )			(4,077 )			—			—
Weighted-average number of ordinary shares outstanding – basic and diluted		22,378,876			23,483,915			51,309,631			51,309,631			17,324,848			17,324,848


Loss per share—basic and diluted		(10.38	)		(14.23	)		(6.88	)		(1.05	)		(6.88	)		(1.05	)

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2020

Summary of Relationship With Related Party

a)	Related Parties


Name of related parties		Relationship
Yusheng Han		Shareholder of a shareholder of the Company, Chief Executive Officer, director
Shaokun Chuai		Shareholder of a shareholder of the Company, Chief Operating Officer, director
Dan Zhou		Shareholder of a shareholder of the Company, management of the Group
BRT Bio Tech Limited		Controlling shareholder of the Company up to October 30, 2019
EaSuMed Holding Ltd.		Equity method investee

Summary of Related Party Balances

b)	The Group had the following related party balances at the end of the year:


	As of December 31,
	2019		2020
	RMB		RMB		US$
Yusheng Han		56,330		—		—
Shaokun Chuai		18,038		—		—
EaSuMed Holding Ltd.		—		212		32

Total amounts due from related parties		74,368		212		32

Summary of Related Party Transactions

c)	The Group had the following related party transactions:


	For the years ended December 31,
	2018		2019		2020
	RMB		RMB		RMB		US$
Service received from:
EaSuMed Holding Ltd.		1,225		806		770		118

Borrowings provided to:
Yusheng Han (i)		—		37,034		—		—
Shaokun Chuai (ii)		—		16,816		—		—
Dan Zhou		30		—		—		—

		30		53,850		—		—

Shares repurchased from:
BRT Bio Tech Limited (iii)		1,500		1,294		—		—

Interest income from:
Yusheng Han		—		1,295		176		27
Shaokun Chuai		—		591		295		45

		—		1,886		471		72

(i)	On March 29, 2019, the Group entered into a loan agreement with Yusheng Han with a principal amount of US$5,500 at the simple rate of 4.5% per annum. The loan which was fully repaid in February and March 2020.

(ii)	On March 28, 2019, the Group entered into a loan agreement with Shaokun Chuai with a principal amount of US$2,500 at the simple rate of 4.5% per annum. The loan which was fully repaid in May 2020.

(iii)

consideration

of RMB1,500 and RMB1,294.

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Summary of Future Minimum Payments Under Non-Cancelable Operating Leases

As of December 31, 2020, future minimum payments under non-cancelable operating leases with initial terms in excess of one year consist of the following:


	RMB		US$
For the years ending:
2021		16,095		2,467
2022		15,647		2,398
2023		14,453		2,215
2024		7,288		1,117
2025		2,739		420

Total		56,222		8,617

Organization and Basis of Presentation - Summary of Subsidiaries, VIE and VIE's Subsidiaries (Detail)	12 Months Ended
	Dec. 31, 2020
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Mar. 10, 2014
Subsidiaries \| BR Hong Kong Limited
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Apr. 01, 2014
Place of incorporation	Hong Kong
Percentage of legal ownership by the Company	100.00%
Principal activities	Investment holding
Subsidiaries \| Beijing Burning Rock Biotech Co Ltd.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Jun. 13, 2014
Place of incorporation	PRC
Percentage of legal ownership by the Company	100.00%
Principal activities	Trading
Subsidiaries \| Burning Rock Biotechnology (Shanghai) Co Ltd.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Jul. 04, 2016
Place of incorporation	PRC
Percentage of legal ownership by the Company	100.00%
Principal activities	Research and development
VIE \| Burning Rock (Beijing) Biotechnology Co Ltd.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Jan. 07, 2014
Place of incorporation	PRC
Percentage of legal ownership by the Company	0.00%
Principal activities	Holding
VIE's subsidiaries \| Guangzhou Burning Rock Dx Co Ltd.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Mar. 18, 2014
Place of incorporation	PRC
Percentage of legal ownership by the Company	0.00%
Principal activities	Cancer therapy selection test and sales of reagent kits
VIE's subsidiaries \| Guangzhou Burning Rock Medical Equipment Co Ltd.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Jan. 06, 2015
Place of incorporation	PRC
Percentage of legal ownership by the Company	0.00%
Principal activities	Facilitation of laboratory equipment sales
VIE's subsidiaries \| Guangzhou Burning Rock Biotechnology Co Ltd.
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Date of incorporation	Jan. 23, 2018
Place of incorporation	PRC
Percentage of legal ownership by the Company	0.00%
Principal activities	Cancer therapy selection test and sales of reagent kits

Organization and Basis of Presentation - Summary of Financial Information of VIE and VIE's Subsidiaries (Detail)
¥ in Thousands, $ in Thousands

Dec. 31, 2020

CNY (¥)

Dec. 31, 2020

USD ($)

Dec. 31, 2019

CNY (¥)

Dec. 31, 2018

CNY (¥)

Table Text Block Supplement [Abstract]

Cash and cash equivalents

¥ 1,895,308

$ 290,469

¥ 94,235

¥ 93,341

Restricted cash

29,898

4,582

4,009

¥ 1,993

Accounts receivable (net of allowances of RMB12,665 and RMB23,983 (US$3,676) as of December 31, 2019 and 2020, respectively)

88,218

13,520

88,822

Contract assets

22,534

3,453

909

Amounts due from related parities

212

74,368

Inventories

68,021

10,425

58,116

Prepayments and other current assets

57,329

8,789

72,340

Total current assets

2,523,652

386,769

706,787

Property and equipment, net

111,481

17,085

89,314

Intangible assets, net

3,457

530

343

Other non-current assets

23,021

3,528

10,954

Total non-current assets

139,376

21,360

140,770

TOTAL ASSETS

2,663,028

408,129

847,557

Accounts payable

35,482

5,438

12,348

Deferred revenue

74,402

11,403

49,539

Capital lease obligations, current

4,816

738

4,893

Customer deposits

1,120

172

4,104

Short-term borrowings

7,370

1,130

2,370

Current portion of long-term borrowings

34,695

5,317

37,129

Total current liabilities

241,533

37,018

164,442

Deferred government grant

263

991

Capital lease obligations

4,816

Long-term borrowings

18,266

Total non-current liabilities

491

47,576

TOTAL LIABILITIES

242,024

37,093

212,018

VIE and subsidiaries of the VIE

Table Text Block Supplement [Abstract]

Cash and cash equivalents

149,736

22,948

28,102

Restricted cash

263

4,009

Accounts receivable (net of allowances of RMB12,665 and RMB23,983 (US$3,676) as of December 31, 2019 and 2020, respectively)

88,217

13,520

88,555

Contract assets

22,534

3,453

909

Amounts due from related parities

212

2,052

Inter-company receivables

^[1]

8,432

1,292

7,232

Inventories

61,374

9,406

49,662

Prepayments and other current assets

17,548

2,692

15,931

Total current assets

348,316

53,383

196,452

Property and equipment, net

32,342

4,957

33,246

Intangible assets, net

Other non-current assets

5,797

888

3,171

Total non-current assets

38,216

5,857

36,508

TOTAL ASSETS

386,532

59,240

232,960

Accounts payable

26,871

4,118

10,068

Deferred revenue

74,402

11,403

49,539

Inter-company payables

^[1]

495,526

75,943

273,772

Capital lease obligations, current

4,816

738

4,893

Accrued liabilities and other current liabilities

54,271

8,317

38,422

Customer deposits

1,120

172

4,104

Short-term borrowings

7,370

1,130

2,370

Current portion of long-term borrowings

266

30,987

Total current liabilities

664,642

101,862

414,155

Deferred government grant

263

991

Capital lease obligations

4,816

Long-term borrowings

266

Total non-current liabilities

263

6,073

TOTAL LIABILITIES

¥ 664,905

$ 101,902

¥ 420,228

[1]	Inter-company receivables/payables represent balances of VIE and subsidiaries of the VIE due from/to the Company and the Group’s consolidated subsidiaries.

Organization and Basis of Presentation - Summary of Financial Information of VIE and VIE's Subsidiaries (Parenthetical) (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Table Text Block Supplement [Abstract]
Accounts Receivable, Allowance	¥ 24,215	$ 3,711	¥ 13,112
Variable Interest Entity, Primary Beneficiary [Member]
Table Text Block Supplement [Abstract]
Accounts Receivable, Allowance	¥ 23,983	$ 3,676	¥ 12,665

Organization and Basis of Presentation - Summary of Operations and Comprehensive Loss Statements of VIE and VIE's Subsidiaries (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Revenues	¥ 429,903	$ 65,885	¥ 381,677	¥ 208,867
Net loss	(407,235)	(62,412)	(169,156)	(177,497)
VIE and subsidiaries of the VIE
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Revenues	432,142	66,229	381,460	204,310
Net loss	¥ (244,765)	$ (37,510)	¥ (72,015)	¥ (93,455)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Organization and Basis of Presentation - Summary of Cash Flow Statement of VIE and VIE's Subsidiaries (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Net cash (used in) generated from operating activities	¥ (73,543)	$ (11,271)	¥ (228,041)	¥ (148,780)
Net cash used in investing activities	(109,312)	(16,752)	(346,660)	106,091
Net cash generated from (used in) financing activities	2,165,719	331,910	571,735	83,393
VIE and subsidiaries of the VIE
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]
Net cash (used in) generated from operating activities	158,563	24,301	(4,993)	(44,153)
Net cash used in investing activities	(9,795)	(1,501)	(56,052)	(7,908)
Net cash generated from (used in) financing activities	¥ (30,880)	$ (4,733)	¥ 34,540	¥ 79,261

Organization and Basis of Presentation - Additional Information (Detail) ¥ in Thousands, $ in Thousands			7 Months Ended	12 Months Ended
	Jan. 30, 2020	Jun. 20, 2014	Dec. 31, 2020 USD ($) shares	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Entity Incorporation, Date of Incorporation				Mar. 10, 2014
Assets				¥ 2,663,028	$ 408,129	¥ 847,557
Adr conversion ratio	1		16.50
Net proceeds from issuance of stock \| ¥				701
IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Newly issued shares through offering			13,500,000
Over-Allotment Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Newly issued shares through offering			2,025,000
Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Newly issued shares through offering			1,515,151
ADR [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net proceeds from issuance of stock \| $			$ 259,892
ADR [Member] \| IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Newly issued shares through offering			13,500,000
Adr conversion ratio			1
ADR [Member] \| Over-Allotment Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Newly issued shares through offering			2,025,000
Adr conversion ratio			1
ADR [Member] \| Private Placement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Newly issued shares through offering			1,515,151
Exclusive Business Cooperation Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangement Term Of Contract		20 years
Collaborative Arrangement Renewal Term		10 years
Variable Interest Entity, Primary Beneficiary [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Assets				386,532	59,240	232,960
Variable Interest Entity, Primary Beneficiary [Member] \| Asset Pledged as Collateral [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Assets \| ¥				0		0
VIEs And Subsidiaries Of VIEs [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net Liabilities				¥ 278,373	$ 42,662	¥ 187,268

Summary of Significant Accounting Policies - Schedule of Fair Value of Warrant Liability Measured on Recurring Basis Using Significant Unobservable Inputs (Detail) - Fair Value, Inputs, Level 3 [Member]	12 Months Ended
	Dec. 31, 2020 $ / shares
Series C Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair market value of warrants	$ 12.08
Warrant [Member] \| Black-Scholes option pricing model [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Volatility for Black-Scholes option pricing model	45.00%

Summary of Significant Accounting Policies - Summary of Warrants Measured at Fair Value on a Recurring Basis (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Class of Warrant or Right [Line Items]
Beginning balance	¥ 23,503
Fair value change	(3,503)	$ (537)	¥ 2,839	¥ 0
Ending balance	0	0	23,503
Fair Value, Recurring [Member]
Class of Warrant or Right [Line Items]
Beginning balance	23,503
Fair value change	(3,503)
Foreign exchange translation	(260)
Exercise of Series C Warrant (note 12)	(19,740)
Ending balance	0		¥ 23,503
The amount of total loss for the year ended December 31, 2020 included in losses	¥ 3,503	$ 537

Summary of Significant Accounting Policies - Summary of Property and Equipment Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2020
Machinery and Laboratory Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment, Useful Life	6 years
Furniture and Tools [Member]
Property, Plant and Equipment, Useful Life	5 years
Electronic Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Estimated Useful Lives	Lesser of lease terms or estimated useful lives of the assets

Summary of Significant Accounting Policies - Summary of Intangible Assets Estimated Useful Livess (Detail)	12 Months Ended
	Dec. 31, 2020
Computer Software [Member]
Finite-Lived Intangible Asset, Useful Life	3 years

Summary of Significant Accounting Policies - Additional Information (Detail) ¥ in Thousands, $ in Thousands			7 Months Ended	12 Months Ended
	Jan. 30, 2020	Jan. 31, 2017 USD ($)	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 CNY (¥) Customer	Dec. 31, 2020 USD ($) Customer	Dec. 31, 2019 CNY (¥) Customer	Dec. 31, 2019 USD ($) Customer	Dec. 31, 2018 CNY (¥) Customer	Dec. 31, 2020 USD ($)	Oct. 31, 2020	Jan. 22, 2020 shares	Apr. 30, 2019	May 01, 2018	Dec. 31, 2017
Convenience translation rate			6.5250	6.5250					6.5250
Equity method investment realized gain loss				¥ 275	$ 42	¥ 230		¥ 422
Equity Method Investment impairment loss				0
Impairment of long lived assets				0		0		0
Breakage Income				11,900	1,824	14,723		0
Increase decrease in deferred revenue				24,863	3,810	(6,307)		27,264
Deferred revenue recognized				27,807	4,262	41,255		26,587
Impairment loss on contract assets				3,497	536	0		0
Remaining performance obligation			¥ 115,523	¥ 115,523		56,110			$ 17,705
Value added tax rate												13.00%	16.00%	17.00%
Minimum percentage of lease term on estimated remaining economic life			75.00%	75.00%					75.00%
Percentage of minimum lease payments at the beginning of lease term			90.00%	90.00%					90.00%
Employee benefit expenses				¥ 28,232	$ 4,327	¥ 29,825		¥ 20,566
Assets held at major financial institutions			¥ 2,287,338	¥ 2,287,338					$ 350,550
Foreign currency exchange rate, Appreciation depreciation percentage				6.30%	6.30%	1.30%	1.30%	5.70%
Description of reverse stock split	2-for-1
Stock split conversion ratio	1		16.50
Warrants outstanding			¥ 0	¥ 0		¥ 23,503			$ 0
Contract with Customer Asset [Member]
Increase in contract assets						21,625	$ 3,314
Fair Value, Nonrecurring [Member]
Financial assets fair value disclosure						0
Financial liabilities fair value disclosure						0
Fair Value, Recurring [Member]
Warrants outstanding			0	0		¥ 23,503
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair value net derivative asset or liability measured on recurring basis with unobservable inputs			¥ 0	¥ 0
EaSuMed Holding Ltd [Member]
Equity method investment ownership percentage		20.29%								21.04%
Payments to acquire equity method investments \| $		$ 363
Supplier Concentration Risk [Member]
Concentration risk, Percentage				57.00%	57.00%	67.00%	67.00%	52.00%
Geographic Concentration Risk [Member] \| PRC
Concentration risk, Percentage				55.00%	55.00%
Geographic Concentration Risk [Member] \| Non PRC [Member]
Concentration risk, Percentage				45.00%	45.00%
Maximum [Member]
Value added tax rate														17.00%
Minimum [Member]
Value added tax rate			6.00%	6.00%					6.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Number of customers \| Customer				2	2	2	2	0
Concentration risk, Percentage				10.00%	10.00%
Accounts Receivable [Member] \| Minimum [Member] \| Customer Concentration Risk [Member]
Concentration risk, Percentage						10.00%	10.00%	10.00%
Series C Warrant [Member]
Fair value adjustment gain of warrants				¥ 3,503	$ 537
Fair value adjustment loss of warrants						¥ 2,839
Series C Warrant [Member] \| Series C Convertible Redeemable Preferred Stock [Member]
Number of securities called by warrants \| shares											1,064,950

Segment Reporting - Summary of Segment Reporting Information (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Revenues:
Revenues from services	¥ 311,184	$ 47,691	¥ 292,523	¥ 180,187
Revenues from sales of products	118,719	18,194	89,154	28,680
Total revenues	429,903	65,885	381,677	208,867
Cost of revenues:	(115,981)	(17,775)	(108,343)	(73,808)
Gross profit	313,922	$ 48,110	273,334	135,059
Central laboratory business
Revenues:
Revenues from services	297,342		276,254	161,458
Revenues from sales of products	0		0	0
Total revenues	297,342		276,254	161,458
Cost of revenues:	(73,960)		(73,689)	(56,241)
Gross profit	223,382		202,565	105,217
In-hospital business
Revenues:
Revenues from services	(847)		(1,476)	4,506
Revenues from sales of products	118,719		89,154	28,680
Total revenues	117,872		87,678	33,186
Cost of revenues:	(35,849)		(29,506)	(13,120)
Gross profit	82,023		58,172	20,066
Pharma research and development services
Revenues:
Revenues from services	14,689		17,745	14,223
Revenues from sales of products	0		0	0
Total revenues	14,689		17,745	14,223
Cost of revenues:	(6,172)		(5,148)	(4,447)
Gross profit	¥ 8,517		¥ 12,597	¥ 9,776

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Segment Reporting - Summary of Total Long Lived Assets By Geographical Location (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Schedule of long lived assets by geographical areas [Line item]
Long-lived assets	¥ 134,502	$ 20,613	¥ 100,268
PRC
Schedule of long lived assets by geographical areas [Line item]
Long-lived assets	106,087	16,258	93,454
United States
Schedule of long lived assets by geographical areas [Line item]
Long-lived assets	¥ 28,415	$ 4,355	¥ 6,814

Accounts Receivable, Net - Summary of Account Receivable (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Receivables [Abstract]
Accounts receivable	¥ 112,433	$ 17,231	¥ 101,934
Allowance for doubtful accounts	(24,215)	(3,711)	(13,112)
Accounts Receivable, Net	¥ 88,218	$ 13,520	¥ 88,822

Accounts Receivable, Net - Summary of Movement in the Allowances for Doubtful Accounts (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Receivables [Abstract]
Balance at the beginning of the year	¥ 13,112	$ 2,010	¥ 1,827	¥ 920
Provisions	13,647	2,091	11,932	907
Write-offs	(2,544)	(390)	(647)	0
Balance at the end of the year	¥ 24,215	$ 3,711	¥ 13,112	¥ 1,827

Inventories - Summary of Inventories (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Inventory, Work in Process and Raw Materials [Abstract]
Raw materials	¥ 27,637	$ 4,236	¥ 24,877
Work in progress	24,849	3,808	19,182
Finished goods	15,535	2,381	14,057
Inventory, Net	¥ 68,021	$ 10,425	¥ 58,116

Prepayments And Other Current Assets - Summary of Prepayments And Other Current Assets (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Deferred Costs Capitalized Prepaid And Other Assets [Abstract]
Deductible input VAT	¥ 34,157	$ 5,235	¥ 37,254
Prepayments	14,773	2,267	14,217
Deferred IPO costs			9,686
Deposits	5,258	806	2,663
Interest receivables	2,016	309	7,194
Others	1,125	172	1,326
Prepayments and other Current Asset	¥ 57,329	$ 8,789	¥ 72,340

Property And Equipment, Net - Summary of Property And Equipment Consist of The Following (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	¥ 230,549	$ 35,333	¥ 182,350
Accumulated depreciation	(119,068)	(18,248)	(93,036)
Property, Plant and Equipment, Net	111,481	17,085	89,314
Machinery And Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	153,589	23,537	120,478
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,588	397	2,296
Furniture And Tools [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	10,085	1,546	7,541
Electronic Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	32,526	4,985	26,708
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	30,672	4,701	24,653
Construction In Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	¥ 1,089	$ 167	¥ 674

Property And Equipment, Net - Summarry of Future Minimum Capital lease Payments Were As Follows (Detail) - Dec. 31, 2020 ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)
2021	¥ 5,111	$ 783
Total minimum capital lease payments	5,111	783
Less: Interest component	(295)	(45)
Present value of minimum capital lease payments	¥ 4,816	$ 738

Property And Equipment, Net - Additional Information (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)	Dec. 31, 2020 USD ($)
Depreciation	¥ 32,457	$ 4,974	¥ 30,819	¥ 24,498
Capital Leases,Accumulated Depreciation	7,455		3,608		$ 1,143
Laboratory Equipment [Member]
Capital Leased Assets, Gross	14,794		14,794		2,267
Electronic Equipment [Member]
Capital Leased Assets, Gross	3,048		3,048		467
Furniture And Tools [Member]
Capital Leased Assets, Gross	¥ 402		¥ 402		$ 62

Intangible Assets, Net - Summary of Intangible Assets (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Finite-Lived Intangible Assets [Line Items]
Computer software	¥ 5,596	$ 858	¥ 1,643
Accumulated amortization	(2,139)	(328)	(1,300)
Intangible assets net (excluding goodwill)	¥ 3,457	$ 530	¥ 343

Intangible Assets, Net - Additional Information (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
IntangibleAssets [Abstract]
Amortization expenses	¥ 852	$ 131	¥ 540	¥ 181
Year 1	1,455
Year 2	1,347
Year 3	655
Year 4	0
Year 5	¥ 0

Accrued Liabilities And Other Current Liabilities - Summary of Accrued Liabilities and Other Current Liabilities (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Payables and Accruals [Abstract]
Accrued payroll and welfare	¥ 39,497	$ 6,053	¥ 25,366
Interests payable	711	109	593
Accrued reimbursement expenses	25,991	3,983	8,937
Professional service fees	5,695	873	9,707
Other taxes and surcharge	6,989	1,071	6,380
Others	4,765	731	3,076
Accrued liabilities and other liabilities	¥ 83,648	$ 12,820	¥ 54,059

Borrowings - Additional Information (Detail) ¥ in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2018 CNY (¥)	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 CNY (¥)	Dec. 31, 2020 USD ($)	Nov. 30, 2020 CNY (¥)	Sep. 30, 2019 CNY (¥)	May 31, 2018 CNY (¥)
Debt Instrument [Line Items]
Short term loan from bank								¥ 5,000
Drew down of debt		¥ 5,000	$ 767	¥ 4,630		¥ 3,000
Debt instrument, fixed interest rate		5.00%					5.00%	3.60%
Short-term borrowings		¥ 7,370		¥ 2,370			$ 1,130
Repayable of debt		34,695	5,317
Two Third-Party Individuals
Debt Instrument [Line Items]
Short-term borrowings		¥ 2,370					$ 363
China Merchants Bank [Member] \| Two Year Loan Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity									¥ 33,000
Debt instrument, fixed interest rate		4.28%		4.28%			4.28%
Proceeds from lines of credit		¥ 18,208	2,790	¥ 14,720
Line of credit facility, annual principal payment		1,780	273	1,500	$ 230
SPD Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	¥ 80,000
Proceeds from lines of credit						¥ 77,455
Line of credit facility, current borrowing capacity	¥ 10,000
Effective interest rate	6.50%
Line of credit facility, remaining borrowing capacity	¥ 70,000
Effective interest rate	7.00%
Line of credit facility, annual principal payment		¥ 30,489	$ 4,637	¥ 46,966
SPD Silicon Valley Bank [Member] \| Accounts Receivable [Member]
Debt Instrument [Line Items]
Debt instrument, collateral amount	¥ 34,807
Zhongguancun Technology Leasing Co LTD [Member] \| Three Year Financing Agreement [Member] \| Machinery And Laboratory Equipment [Member]
Debt Instrument [Line Items]
Debt instrument, fixed interest rate										5.80%
Debt instrument, collateral amount										¥ 32,405

Convertible Notes - Additional Information (Detail) ¥ in Thousands, $ in Thousands	1 Months Ended				5 Months Ended	12 Months Ended
	Jan. 31, 2019 CNY (¥) shares	Jan. 31, 2017 CNY (¥) shares	Jan. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($)	May 31, 2017 USD ($)	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)	Nov. 30, 2020	Aug. 31, 2016 USD ($)	Aug. 31, 2015 USD ($)
Debt instrument interest rate						5.00%	5.00%			3.60%
Repayments of convertible debt						¥ 38,909	$ 5,963	¥ 87,024	¥ 8,168
Convertible Debt [Member]
Debt conversion, converted instrument, amount \| ¥		¥ 110,485
Gain (loss) on debt conversion \| ¥	¥ 0	¥ 0
Convertible Debt [Member] \| Series A Plus Convertible Notes [Member]
Debt instrument face amount				$ 100								$ 7,900
Debt instrument interest rate				15.00%
Debt instrument, convertible, conversion price percentage				95.00%
Debt instrument, redemption, description				The redemption date will be automatically extended by six months if the Group does not complete its Series B Financing by the first anniversary of the issuance date.
Repayments of convertible debt			$ 2,502
Convertible Debt [Member] \| Series A Plus Supplementary convertible Note [Member]
Debt instrument face amount											$ 8,000
Debt instrument interest rate											20.00%
Convertible Debt [Member] \| Series B convertible Note [Member]
Debt instrument face amount					$ 17,000
Debt instrument interest rate					9.00%
Debt instrument, convertible, conversion price percentage					95.00%
Debt instrument, redemption, description					The redemption date will be automatically extended by six months if the Group does not complete its Series C Financing by the second anniversary of the issuance date.
Debt conversion, converted instrument, amount \| ¥	¥ 127,982
Series B Convertible Preferred Stock [Member]
Debt converted instrument, shares issued \| shares		4,063,310	4,063,310
Series C Convertible Preferred Stock [Member]
Debt converted instrument, shares issued \| shares	2,033,485

Convertible Preferred Shares And Warrant - Additional Information (Detail) $ / shares in Units, ¥ in Thousands, $ in Thousands		1 Months Ended									12 Months Ended				13 Months Ended	20 Months Ended
	Jan. 22, 2020 shares	May 31, 2020 CNY (¥) shares	Jan. 31, 2020 USD ($) $ / shares shares	Oct. 31, 2019 CNY (¥) shares	Oct. 31, 2019 USD ($) $ / shares shares	Jan. 31, 2019 CNY (¥) shares	Jan. 31, 2019 USD ($) shares	Dec. 31, 2018 CNY (¥) shares	Jan. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2014 USD ($) $ / shares shares	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 CNY (¥) shares	Dec. 31, 2019 USD ($) $ / shares shares	Aug. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Sep. 30, 2020 shares	Jan. 31, 2019 $ / shares
Convertible Preferred Shares And Warrant [Line Items]
Class of warrants or rights outstanding																	0
Temporary equity reverse stock split ratio			2:1
Temporary equity dividend declared \| $												$ 0		$ 0		$ 0
Convertible Warrants [Member]
Convertible Preferred Shares And Warrant [Line Items]
Class of warrant or rights fair value \| ¥						¥ 19,821
Gain loss recognised due to change in fair value of warrant liabilities											¥ 3,503	$ 537	¥ 2,839
Series C Warrants [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity shares repurchased during the period shares		55,243
Payments for the repurchase of redeemable non controlling interest \| ¥		¥ 3,500
Difference between carrying value and fair value of temporary equity \| ¥											¥ 227
Series C Warrants [Member] \| Conversion Of Series C Redeemable Convertible Preferred Stock [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity shares issued during the period on warrant excercise	1,064,950
Series A Redeemable Convertible Preferred Stock [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity stock issued during the period shares										22,714,874
Temporary equity issue price per share \| $ / shares										$ 0.24
Proceeds from issue of redeemable convertible preferred stock \| $										$ 5,459
Temporary equity liquidation preference as a percentage of issue price												150.00%
Temporary equity redemption price as a percentage of principal												200.00%
Series A Plus Redeemable Convertible Preferred Stock [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity stock issued during the period shares									130,511						10,599,927
Temporary equity issue price per share \| $ / shares									$ 1.66						$ 1.26
Proceeds from issue of redeemable convertible preferred stock \| $									$ 217						$ 13,356
Temporary equity liquidation preference as a percentage of issue price												150.00%
Temporary equity interest payable percentage												12.00%
Temporary equity shares repurchased during the period shares				4,438	4,438	15,784	15,784	124,985
Payments for the repurchase of redeemable non controlling interest \| ¥				¥ 294		¥ 1,000		¥ 1,500
Difference between carrying value and fair value of temporary equity \| ¥				84		216		127
Series A Plus Redeemable Convertible Preferred Stock [Member] \| BR Hong Kong Limited \| Subsidiaries \| Compensation Expenses [Member]
Convertible Preferred Shares And Warrant [Line Items]
Gain loss on redemption of redeemable non controlling interest \| ¥				¥ 160		¥ 611		¥ 0
Series B Redeemable Preferred Stock [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity stock issued during the period shares									7,020,059							1,685,348
Temporary equity issue price per share \| $ / shares									$ 3.96							$ 3.96
Proceeds from issue of redeemable convertible preferred stock \| $									$ 27,812							$ 6,677
Temporary equity interest payable percentage												12.00%
Series B Redeemable Preferred Stock [Member] \| Conversion Of Redeemable Convertible Series A Plus Notes [Member]
Convertible Preferred Shares And Warrant [Line Items]
Debt converted instrument, convertible preferred shares issued									4,063,310
Series C Redeemable Convertible Preferred Stock [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity stock issued during the period shares				231,198	231,198	10,238,825	10,238,825						21,299	21,299
Temporary equity issue price per share \| $ / shares					$ 9.39									$ 9.39				$ 9.39
Proceeds from issue of redeemable convertible preferred stock					$ 2,171	¥ 766,127	$ 96,144							$ 200
Temporary equity interest payable percentage												12.00%
Series C Redeemable Convertible Preferred Stock [Member] \| Rank One [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity liquidation preference as a percentage of issue price												120.00%
Series C Redeemable Convertible Preferred Stock [Member] \| Rank Two [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity liquidation preference as a percentage of issue price												150.00%
Series C Redeemable Convertible Preferred Stock [Member] \| Conversion Of Redeemable Convertible Series B Notes [Member]
Convertible Preferred Shares And Warrant [Line Items]
Debt converted instrument, convertible preferred shares issued						2,033,485	2,033,485
Series C Redeemable Convertible Preferred Stock [Member] \| Series C Warrants [Member]
Convertible Preferred Shares And Warrant [Line Items]
Class of warrant or rights number of securities called by warrants or rights												1,064,950
Class of warrant or right exercise price \| $ / shares												$ 9.39
Series C Plus Redeemable Convertible Preferred Stock [Member]
Convertible Preferred Shares And Warrant [Line Items]
Temporary equity stock issued during the period shares			2,129,472
Temporary equity issue price per share \| $ / shares			$ 13.62
Proceeds from issue of redeemable convertible preferred stock \| $			$ 29,000
Redeemable Convertible Preferred Stock [Member]
Convertible Preferred Shares And Warrant [Line Items]
Common stock conversion ratio											1	1

Convertible Preferred Shares And Warrant - Schedule of Change in Carring Value of Preferred Shares (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Redeemable Noncontrolling Interest [Line Items]
Beginning Balance	¥ 1,527,033	¥ 596,118	¥ 540,642
Issuance of Series preferred shares	201,118	766,127	2,000
Accretion of Preferred Shares	64,688	165,011	54,849
Repurchase of Preferred Shares	(3,727)	(223)	(1,373)
Exercise of Series C Warrant	88,593
Conversion to ordinary shares	(1,877,705)
Ending Balance		1,527,033	596,118
Series A Redeemable Convertible Preferred Stock [Member]
Redeemable Noncontrolling Interest [Line Items]
Beginning Balance	57,849	53,331	48,985
Accretion of Preferred Shares	2,068	4,518	4,346
Conversion to ordinary shares	(59,917)
Ending Balance		57,849	53,331
Series A Plus Redeemable Convertible Preferred Stock [Member]
Redeemable Noncontrolling Interest [Line Items]
Beginning Balance	129,142	118,163	108,764
Accretion of Preferred Shares	5,074	11,202	10,772
Repurchase of Preferred Shares		(223)	(1,373)
Conversion to ordinary shares	(134,216)
Ending Balance		129,142	118,163
Series B Redeemable Preferred Stock [Member]
Redeemable Noncontrolling Interest [Line Items]
Beginning Balance	466,983	424,624	382,893
Issuance of Series preferred shares			2,000
Accretion of Preferred Shares	19,167	42,359	39,731
Conversion to ordinary shares	(486,150)
Ending Balance		466,983	¥ 424,624
Series C Redeemable Convertible Preferred Stock [Member]
Redeemable Noncontrolling Interest [Line Items]
Beginning Balance	873,059
Issuance of Series preferred shares		766,127
Accretion of Preferred Shares	28,061	106,932
Repurchase of Preferred Shares	(3,727)
Exercise of Series C Warrant	88,593
Conversion to ordinary shares	(985,986)
Ending Balance		873,059
Series C Plus Redeemable Convertible Preferred Stock [Member]
Redeemable Noncontrolling Interest [Line Items]
Beginning Balance	0
Issuance of Series preferred shares	201,118
Accretion of Preferred Shares	10,318
Conversion to ordinary shares	¥ (211,436)
Ending Balance		¥ 0

Share-Based Compensation - Summary of Stock Options Valuation Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Aug. 19, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate minimum	0.51%	1.63%	2.69%
Risk-free interest rate maximum	1.90%	2.41%	3.05%
Dividend yield	0.00%	0.00%	0.00%
Expected volatility range Minimum	44.90%	44.60%	46.00%
Expected volatility range Maximum	49.30%	45.40%	47.80%
Exercise multiple	$ 2.20		$ 2.20
Contractual life	10 years	10 years	10 years
Fair market value per ordinary share as at valuation dates				$ 9.39
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise multiple		$ 2.80
Fair market value per ordinary share as at valuation dates	$ 27.15	9.41	$ 3.20
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise multiple		2.20
Fair market value per ordinary share as at valuation dates	$ 9.41	$ 3.30	$ 2.32

Share-Based Compensation - Summary of Share Options Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Number of Options, Outstanding Beginning	2,403,799	3,050,168	3,248,211
Number of Options, Granted	5,771,720	1,273,346	652,723
Number of Options, Exercised	(233,440)	(1,864,343)	(818,554)
Number of Options, Forfeited	(121,650)	(55,372)	(32,212)
Number of Options, Outstanding Ending	7,820,429	2,403,799	3,050,168	3,248,211
Number of Options, Vested and expected to vest	7,820,429
Number of Options, Exercisable	538,300
Weighted-Average Exercise Price, Outstanding beginning	$ 1.5340	$ 0.0002	$ 0.0002
Weighted-Average Exercise Price, Granted	0.0002	2.8957	0.0002
Weighted-Average Exercise Price, Exercised	0.0002	0.0002	0.0002
Weighted-Average Exercise Price, Forfeited	0.0002	0.0002	0.0002
Weighted-Average Exercise Price, Outstanding Ending	0.4717	1.5340	0.0002	$ 0.0002
Weighted-Average Exercise Price, Vested and expected to vest	0.4717
Weighted-Average Exercise Price, Exercisable	6.8495
Weighted-Average Grant Date Fair Value, Outstanding Beginning	3.75	0.97	0.38
Weighted-Average Grant Date Fair Value, Granted	26.75	3.97	2.77
Weighted-Average Grant Date Fair Value, Exercised	1.18	0.30	0.61
Weighted-Average Grant Date Fair Value, Forfeited	3.31	2.90	0.55
Weighted-Average Grant Date Fair Value, Outstanding Ending	21.28	$ 3.75	$ 0.97	$ 0.38
Weighted-Average Grant Date Fair Value, Vested and expected to vest	21.28
Weighted-Average Grant Date Fair Value, Exercisable	$ 2.76
Weighted-Average Remaining Contractual Term, Outstanding	9 years 1 month 6 days	8 years 9 months	7 years 1 month 20 days	7 years 2 months 26 days
Weighted-Average Remaining Contractual Term, Vested and expected to vest	9 years 1 month 6 days
Weighted-Average Remaining Contractual Term, Exercisable	7 years 5 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 176,963	$ 20,079	$ 9,744	$ 6,739
Aggregate Intrinsic Value, Vested and expected to vest	176,963
Aggregate Intrinsic Value, Exercisable	$ 8,748

Share-Based Compensation - Summary of Restricted Share Units (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	5,771,720	1,273,346	652,723
Number of Options, Outstanding Ending	7,820,429	2,403,799	3,050,168	3,248,211
Weighted-Average Exercise Price, Granted	$ 0.0002	$ 2.8957	$ 0.0002
Weighted-Average Exercise Price, Outstanding Ending	0.4717	1.5340	0.0002	$ 0.0002
Weighted-Average Grant Date Fair Value, Granted	26.75	3.97	2.77
Weighted-Average Grant Date Fair Value, Outstanding Ending	$ 21.28	$ 3.75	$ 0.97	$ 0.38
Weighted-Average Remaining Contractual Term, Outstanding	9 years 1 month 6 days	8 years 9 months	7 years 1 month 20 days	7 years 2 months 26 days
Aggregate Intrinsic Value, Outstanding Ending	$ 176,963	$ 20,079	$ 9,744	$ 6,739
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	4,848
Number of Options, Outstanding Ending	4,848
Weighted-Average Exercise Price, Granted	$ 0
Weighted-Average Exercise Price, Outstanding Ending	0
Weighted-Average Grant Date Fair Value, Granted	24.35
Weighted-Average Grant Date Fair Value, Outstanding Ending	$ 24.35
Weighted-Average Remaining Contractual Term, Outstanding	9 years 5 months 15 days
Aggregate Intrinsic Value, Outstanding Ending	$ 111,988

Share-Based Compensation - Summary of Restricted Shares Activities (Detail) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding	743,955	0	0	2,144,423
Number of shares, Vested		(2,144,423)
Number of shares, Granted	$ 743,955
Weighted average grant date fair value, Outstanding	$ 8.74	$ 0	$ 0	$ 0.10
Weighted average grant date fair value, Vested		$ 0.10
Weighted average grant date fair value, Granted	8.74

Share-Based Compensation - Summary of Share-Based Compensation Expenses (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	¥ 173,220	$ 26,547	¥ 22,792	¥ 5,095
Cost of Revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	796	122	678	322
Research and Development Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	49,801	7,630	9,377	2,096
Selling and Marketing Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	3,457	530	1,235	547
General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	¥ 119,166	$ 18,265	¥ 11,502	¥ 2,130

Share-Based Compensation - Additional Information (Detail) $ / shares in Units, ¥ in Thousands, $ in Thousands		6 Months Ended	8 Months Ended	12 Months Ended
	Aug. 19, 2019 USD ($) $ / shares shares	Dec. 31, 2020 CNY (¥) shares	Dec. 31, 2020 CNY (¥) shares	Dec. 31, 2020 CNY (¥) shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 CNY (¥) shares	Dec. 31, 2018 CNY (¥) shares	Dec. 31, 2017	Dec. 31, 2020 USD ($) $ / shares shares	Jun. 25, 2020 $ / shares	May 09, 2020 $ / shares	Dec. 31, 2019 $ / shares	Dec. 31, 2018 $ / shares	Apr. 19, 2018 shares	Aug. 20, 2016 shares	Jun. 20, 2014 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award, number of shares authorized														5,290,234	3,690,599	3,001,365
Options grants in period				5,771,720	5,771,720	1,273,346	652,723
Options vested in period fair value				¥ 3,580	$ 549	¥ 9,485	¥ 491
Compensation cost not yet recognized stock options		¥ 972,698	¥ 972,698	972,698					$ 149,072
Share-based payment arrangement, expense				¥ 173,220	$ 26,547	22,792	¥ 5,095
Share-based compensation, stock issued during period, shares	85,196
Share price \| $ / shares	$ 9.39
Share-based compensation, stock issued during period, value \| $	$ 800
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price \| $ / shares									$ 27.15			$ 9.41	$ 3.20
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price \| $ / shares									$ 9.41			$ 3.30	$ 2.32
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years	4 years
Sharebased payment award expiration period				10 years	10 years
Preferred Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment arrangement, expense \| ¥						¥ 463
Twenty Twenty Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award, number of shares authorized		4,512,276	4,512,276	4,512,276					4,512,276
Equity instruments other than options grants in period				4,848	4,848
Vesting period				4 years	4 years
Sharebased payment award expiration period				10 years	10 years
Awards available for future grant		4,507,428	4,507,428	4,507,428					4,507,428
ESIP NO.1 \| Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of shares			2,614,636
Sale price per share \| $ / shares											$ 13.2
Percentage of restricted shares lockup in first year			10.00%
Percentage of restricted shares lockup in second year			40.00%
Percentage of restricted shares lockup in third year			50.00%
ESIP NO.2 \| Common Class A [Member] \| Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale price per share \| $ / shares										$ 20.02
Percentage of restricted shares lockup in first year		10.00%
Percentage of restricted shares lockup in second year		40.00%
Percentage of restricted shares lockup in third year		50.00%
Maximum subscription amount per person \| ¥		¥ 2,000
Pre-IPO Plan [member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options grants in period				296,327	296,327	1,273,346	652,723
Sharebased payment award expiration period				10 years	10 years
Awards available for future grant		847,415	847,415	847,415					847,415
Pre-IPO Plan [member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years	4 years
Pre-IPO Plan [member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				3 years	3 years
Management Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options grants in period				5,475,393	5,475,393
Vesting period				4 years	4 years
Sharebased payment award expiration period				10 years	10 years
Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum				5.00%	5.00%
Awards available for future grant		111,742	111,742	111,742					111,742
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options grants in period				8.74	8.74
Vesting period				2 years	2 years
Sharebased payment award expiration period				10 years	10 years			4 years
Fair value of the restricted shares				¥ 42,540	$ 6,520
Share-based payment arrangement, expense				¥ 1,671	$ 256	¥ 0	¥ 1,226
Restricted Stock [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								1 year
Share-based payment award vesting rights percentage								25.00%
Restricted Stock [Member] \| Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								3 years
Share-based payment award vesting rights percentage								75.00%
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost not yet recognized period for recognition				3 years 5 months 1 day	3 years 5 months 1 day

Income Taxes - Summary of Group's Loss before Income Taxes (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Total loss before income tax	¥ (407,235)	$ (62,412)	¥ (169,156)	¥ (177,497)
PRC
Total loss before income tax	(366,634)	(56,189)	(150,495)	(157,740)
Non PRC [Member]
Total loss before income tax	¥ (40,601)	$ (6,223)	¥ (18,661)	¥ (19,757)

Income Taxes - Summary of Reconciliation of Effective Tax rate and Statutory Income Tax rate (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Income Tax Disclosure [Abstract]
Loss before income tax	¥ (407,235)	$ (62,412)	¥ (169,156)	¥ (177,497)
Income tax benefits computed at PRC statutory rate (25%)	(101,809)	(15,603)	(42,289)	(44,374)
Effect of tax rate differential	10,375	1,590	10,474	5,052
Research and development super-deduction	(6,011)	(921)	(4,712)	(1,821)
Non-deductible expenses	54,255	8,315	10,629	5,394
Non-taxable income	(872)	(134)	(1,412)	(212)
Changes in valuation allowance	44,062	6,753	27,310	35,961
Income tax expenses	¥ 0	$ 0	¥ 0	¥ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes - Summary of Principle Components of Deferred Tax Assets (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Components of Deferred Tax Assets [Abstract]
Accruals and reserves	¥ 9,205	$ 1,410	¥ 3,913
Net operating loss carried forward	60,288	9,240	52,593
Government grants	39	6	222
Depreciation and amortization	681	104	685
Excessive education fee	654	100	967
Timing difference of research and development expense recognition	90,535	13,875	47,809
Timing difference of revenue recognition	6,425	985	10,160
Excessive donation expense carried forward	2,471	379	1,753
Gross deferred tax assets	170,298	26,099	118,102
Less: Valuation allowance	(170,298)	(26,099)	¥ (118,102)
Total deferred tax assets, net	¥ 0	$ 0

Income Taxes - Additional Information (Detail) ¥ in Thousands, $ in Thousands		12 Months Ended
	Jan. 01, 2008	Dec. 31, 2020 CNY (¥)	Dec. 31, 2018	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Unrecognized Tax Benefits		¥ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense		¥ 0
CHINA
Income tax rate	25.00%	25.00%
Net operating loss carried forward		¥ 241,152		$ 36,958	¥ 210,376
Operating Loss Carryforwards, Expiration Term			5 years
CHINA \| High and New Technology Enterprise [Member]
Income tax rate	15.00%	15.00%
Operating Loss Carryforwards, Expiration Term			10 years
UNITED STATES
Income tax rate		21.00%
State income tax rate		8.80%
HONG KONG
Income tax rate		16.50%

Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Detail) ¥ / shares in Units, $ / shares in Units, ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥) ¥ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 CNY (¥) ¥ / shares shares	Dec. 31, 2018 CNY (¥) ¥ / shares shares
Numerator:
Net loss attributable to Burning Rock Biotech Limited's shareholders	¥ (407,235)	$ (62,412)	¥ (169,156)	¥ (177,497)
Accretion of convertible preferred shares	64,688	9,914	165,011	54,849
Net loss attributable to ordinary shareholders	¥ (471,923)	$ (72,326)	¥ (334,167)	¥ (232,346)
Denominator:
Weighted-average number of ordinary shares outstanding - basic and diluted	0	0	23,483,915	22,378,876
Loss per share - basic and diluted \| (per share)	¥ 0	$ 0	¥ (14.23)	¥ (10.38)
Common Class A [Member]
Denominator:
Effect of unvested restricted shares	(4,077)	(4,077)
Weighted-average number of ordinary shares outstanding - basic and diluted	51,309,631	51,309,631	0	0
Loss per share - basic and diluted \| (per share)	¥ (6.88)	$ (1.05)	¥ 0	¥ 0
Common Class B [Member]
Denominator:
Weighted-average number of ordinary shares outstanding - basic and diluted	17,324,848	17,324,848	0	0
Loss per share - basic and diluted \| (per share)	¥ (6.88)	$ (1.05)	¥ 0	¥ 0
Common Stock
Numerator:
Net loss attributable to Burning Rock Biotech Limited's shareholders \| ¥			¥ (169,156)	¥ (177,497)
Accretion of convertible preferred shares \| ¥			(165,011)	(54,849)
Net loss attributable to ordinary shareholders \| ¥			¥ (334,167)	¥ (232,346)
Denominator:
Weighted-average number of ordinary shares outstanding			23,483,915	22,378,876
Weighted-average number of ordinary shares outstanding - basic and diluted			23,483,915	22,378,876
Loss per share - basic and diluted \| ¥ / shares			¥ (14.23)	¥ (10.38)
Common Stock \| Common Class A [Member]
Numerator:
Net loss attributable to Burning Rock Biotech Limited's shareholders	¥ (304,440)	$ (46,658)
Accretion of convertible preferred shares	(48,359)	(7,411)
Net loss attributable to ordinary shareholders	¥ (352,799)	$ (54,069)
Denominator:
Weighted-average number of ordinary shares outstanding	51,313,708	51,313,708
Weighted-average number of ordinary shares outstanding - basic and diluted	51,309,631	51,309,631
Loss per share - basic and diluted \| (per share)	¥ (6.88)	$ (1.05)
Common Stock \| Common Class B [Member]
Numerator:
Net loss attributable to Burning Rock Biotech Limited's shareholders	¥ (102,795)	$ (15,754)
Accretion of convertible preferred shares	(16,329)	(2,503)
Net loss attributable to ordinary shareholders	¥ (119,124)	$ (18,257)
Denominator:
Weighted-average number of ordinary shares outstanding	17,324,848	17,324,848
Weighted-average number of ordinary shares outstanding - basic and diluted	17,324,848	17,324,848
Loss per share - basic and diluted \| (per share)	¥ (6.88)	$ (1.05)

Related Party Transactions - Summary of Relationship With Related Party (Detail)	12 Months Ended
	Dec. 31, 2020
Yusheng Han
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Shareholder of a shareholder of the Company, Chief Executive Officer, director
Shaokun Chuai
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Shareholder of a shareholder of the Company, Chief Operating Officer, director
Dan Zhou
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Shareholder of a shareholder of the Company, management of the Group
BRT Bio Tech Limited
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Controlling shareholder of the Company up to October 30, 2019
EaSuMed Holding Ltd [Member]
Related Party Transaction [Line Items]
Nature of Common Ownership or Management Control Relationships	Equity method investee

Related Party Transactions - Summary of Related Party Balances (Detail) ¥ in Thousands, $ in Thousands	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Related Party Transaction [Line Items]
Amounts due from related parties	¥ 212	$ 32	¥ 74,368
Yusheng Han
Related Party Transaction [Line Items]
Amounts due from related parties			56,330
Shaokun Chuai
Related Party Transaction [Line Items]
Amounts due from related parties			¥ 18,038
EaSuMed Holding Ltd [Member]
Related Party Transaction [Line Items]
Amounts due from related parties	¥ 212	$ 32

Related Party Transactions - Summary of Related Party Transactions (Detail)
¥ in Thousands, $ in Thousands

12 Months Ended

Dec. 31, 2020

CNY (¥)

Dec. 31, 2020

USD ($)

Dec. 31, 2019

CNY (¥)

Dec. 31, 2018

CNY (¥)

Related party transactions

¥ 53,850

¥ 30

Interest income from:

¥ 471

$ 72

1,886

Yusheng Han

Related party transactions

^[1]

37,034

Interest income from:

176

1,295

Shaokun Chuai

Related party transactions

^[2]

16,816

Interest income from:

295

591

Dan Zhou

Related party transactions

BRT Bio Tech Limited

Related party transactions

^[3]

1,294

1,500

EaSuMed Holding Ltd [Member]

Consulting service received from:

¥ 770

$ 118

¥ 806

¥ 1,225

[1]	On March 29, 2019, the Group entered into a loan agreement with Yusheng Han with a principal amount of US$5,500 at the simple rate of 4.5% per annum. The loan which was fully repaid in February and March 2020.
[2]	On March 28, 2019, the Group entered into a loan agreement with Shaokun Chuai with a principal amount of US$2,500 at the simple rate of 4.5% per annum. The loan which was fully repaid in May 2020.
[3]	The Group repurchased 31,246 ordinary shares held by BRT Bio Tech Limited in 2018. The purchase consideration was RMB33,316. The Group repurchased 124,985 and 20,222 Series A+ Preferred shares held by BRT Bio Tech Limited in 2018 and 2019, respectively, at considerations of RMB1,500 and RMB1,294.

Related Party Transactions - Summary of Related Party Transactions (Parenthetical) (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019 CNY (¥) shares	Dec. 31, 2018 CNY (¥) shares	Dec. 31, 2017 CNY (¥)	Dec. 31, 2020	Nov. 30, 2020	Mar. 29, 2019 USD ($)	Mar. 28, 2019 USD ($)
Related Party Transaction [Line Items]
Debt Instrument Interest Rate				5.00%	3.60%
Repurchase of ordinary shares, Value \| ¥			¥ 33,316
Common Stock
Related Party Transaction [Line Items]
Repurchase of ordinary shares, Shares		(31,246)
Preferred Stock \| Series A Plus Preferred Stock
Related Party Transaction [Line Items]
Repurchase of ordinary shares, Shares	20,222	124,985
Repurchase of ordinary shares, Value \| ¥	¥ 1,294	¥ 1,500
Yusheng Han
Related Party Transaction [Line Items]
Debt Instrument Face Amount \| $						$ 5,500
Debt Instrument Interest Rate						4.50%
Shaokun Chuai
Related Party Transaction [Line Items]
Debt Instrument Face Amount \| $							$ 2,500
Debt Instrument Interest Rate							4.50%
BRT Bio Tech Limited \| Common Stock
Related Party Transaction [Line Items]
Repurchase of ordinary shares, Shares		31,246

Related Party Transactions - Additional Information (Detail) - CNY (¥) ¥ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Compensation expense	¥ 0	¥ 771	¥ 0

Commitments and Contingencies - Summary of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail) - Dec. 31, 2020 ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021	¥ 16,095	$ 2,467
2022	15,647	2,398
2023	14,453	2,215
2024	7,288	1,117
2025	2,739	420
Total	¥ 56,222	$ 8,617

Commitments and Contingencies - Additional Information (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)	Dec. 31, 2018 CNY (¥)
Long-term Purchase Commitment [Line Items]
Operating Leases, Rent Expense	¥ 12,103	$ 1,855	¥ 9,435	¥ 8,689
Capital Addition [Member] \| Leasehold Improvements [Member]
Long-term Purchase Commitment [Line Items]
Capital expenditure commitment	¥ 1,540	$ 236

Restricted Net Assets - Additional Information (Detail) ¥ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020 CNY (¥)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 CNY (¥)
Restricted Net Assets [Line Items]
Restricted cash	¥ 502,218	$ 76,968	¥ 360,486
CHINA
Restricted Net Assets [Line Items]
Appropriation of after tax profit to general reserve	10.00%	10.00%
Appropriation of after tax profit to statutory general reserve	50.00%
CHINA \| Variable Interest Entity, Primary Beneficiary [Member]
Restricted Net Assets [Line Items]
Appropriation of after tax profit to general reserve	10.00%	10.00%
Appropriation of after tax profit to statutory general reserve	50.00%